<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">91044</article-id>
<article-id pub-id-type="doi">10.7554/eLife.91044</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.91044.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.2</article-version>
</article-version-alternatives>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neurophysiological trajectories in Alzheimer’s disease progression</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5732-7229</contrib-id>
<name>
<surname>Kudo</surname>
<given-names>Kiwamu</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">†</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ranasinghe</surname>
<given-names>Kamalini G.</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="author-notes" rid="n1">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morise</surname>
<given-names>Hirofumi</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Syed</surname>
<given-names>Faatimah</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sekihara</surname>
<given-names>Kensuke</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3611-0848</contrib-id>
<name>
<surname>Rankin</surname>
<given-names>Katherine P.</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Miller</surname>
<given-names>Bruce L.</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kramer</surname>
<given-names>Joel H.</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rabinovici</surname>
<given-names>Gil D.</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vossel</surname>
<given-names>Keith</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kirsch</surname>
<given-names>Heidi E.</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nagarajan</surname>
<given-names>Srikantan S.</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Biomagnetic Imaging Laboratory, Department of Radiology and Biomedical Imaging, University of California</institution>, San Francisco, CA, 94143, <country>USA</country></aff>
<aff id="a2"><label>2</label><institution>Medical Imaging Business Center, Ricoh Company, Ltd.</institution>, Kanazawa, 920-0177, <country>Japan</country></aff>
<aff id="a3"><label>3</label><institution>Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California</institution>, San Francisco, CA, 94158, <country>USA</country></aff>
<aff id="a4"><label>4</label><institution>Signal Analysis Inc.</institution>, Hachioji, Tokyo, 192-0031, <country>Japan</country></aff>
<aff id="a5"><label>5</label><institution>Department of Radiology and Biomedical Imaging, University of California</institution>, San Francisco, CA, 94143, <country>USA</country></aff>
<aff id="a6"><label>6</label><institution>Mary S. Easton Center for Alzheimer’s Research and Care, Department of Neurology, David Geffen School of Medicine, University of California Los Angeles</institution>, Los Angeles, CA 90095, <country>USA</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Herrmann</surname>
<given-names>Björn</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Baycrest Hospital</institution>
</institution-wrap>
<city>Toronto</city>
<country>Canada</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Behrens</surname>
<given-names>Timothy E</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>University of Oxford</institution>
</institution-wrap>
<city>Oxford</city>
<country>United Kingdom</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label><bold>For correspondence:</bold> <email>kiwamu.kudo@jp.ricoh.com</email> (KK)</corresp>
<fn id="n1" fn-type="equal"><label>†</label><p>These authors contributed equally to this work</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2023-10-09">
<day>09</day>
<month>10</month>
<year>2023</year>
</pub-date>
<volume>12</volume>
<elocation-id>RP91044</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2023-08-09">
<day>09</day>
<month>08</month>
<year>2023</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2023-08-09">
<day>09</day>
<month>08</month>
<year>2023</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.05.18.541379"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2023, Kudo et al</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Kudo et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-91044-v1.pdf"/>
<abstract>
<title>Abstract</title>
<p>Alzheimer’s disease (AD) is characterized by accumulation of amyloid-<italic>β</italic> and misfolded tau proteins causing synaptic dysfunction and progressive neurodegeneration and cognitive decline. Altered neural oscillations have been consistently demonstrated in AD. However, the trajectories of abnormal neural oscillations in AD progression and their relationship to neurodegeneration and cognitive decline are unknown. Here, we deployed robust event-based sequencing models (EBMs) to investigate the trajectories of long-range and local neural synchrony across AD stages, estimated from resting-state magnetoencephalography. Increases in neural synchrony in the delta-theta band and decreases in the alpha and beta bands showed progressive changes along the EBM stages. Decreases in alpha and beta-band synchrony preceded both neurodegeneration and cognitive decline, indicating that frequency-specific neuronal synchrony abnormalities are early manifestations of AD pathophysiology. The long-range synchrony effects were greater than the local synchrony, indicating a greater sensitivity of connectivity metrics involving multiple regions of the brain. These results demonstrate the evolution of functional neuronal deficits along the sequence of AD progression.</p>
</abstract>

</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>K.K. and H.M. are employees of Ricoh Company, Ltd.</p></notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>Section structure updated.</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Alzheimer’s disease (AD) is a neurodegenerative disease characterized by amyloid-<italic>β</italic> (A<italic>β</italic>) and neurofibrillary tangles of abnormally phosphorylated tau (<bold><italic><xref ref-type="bibr" rid="c13">DeTure and Dickson (2019</xref></italic></bold>)). Clinical and epidemiological studies have suggested that A<italic>β</italic> accumulation occurs early in the timeline of neuropathological changes in AD, likely preceding the accumulation of tau, and subsequent neurodegeneration and cognitive decline (<bold><italic><xref ref-type="bibr" rid="c26">Jack Jr et al., 2010</xref></italic></bold>; <bold><italic><xref ref-type="bibr" rid="c55">Sperling et al., 2011</xref></italic></bold>). The neuropathological changes of AD are therefore described as a continuum, starting from the presymptomatic stage of proteinopathy and continuing to progress during the symptomatic stage with increasing stages of disease severity (<bold><italic><xref ref-type="bibr" rid="c55">Sperling et al., 2011</xref>; <xref ref-type="bibr" rid="c24">Jack Jr et al., 2018</xref></italic></bold>). Transgenic mouse models of AD have shown that AD proteinopathy of A<italic>β</italic> and tau is associated with synaptic and circuit dysfunctions in neural networks (<bold><italic><xref ref-type="bibr" rid="c7">Busche et al., 2008</xref>; <xref ref-type="bibr" rid="c2">Ahnaou et al., 2017</xref>; <xref ref-type="bibr" rid="c8">Busche et al., 2019</xref></italic></bold>). However, the temporal change in synaptic and circuit dysfunction along disease progression in patients with AD remains largely unknown.</p>
<p>Functional deficits in neural networks, especially in the presymptomatic stage, have attracted attention in recent years with the rapidly evolving landscape of plasma-biomarkers of early detection and the novel therapeutics showing the benefits of early intervention (<bold><italic><xref ref-type="bibr" rid="c14">Dubois et al., 2016</xref></italic></bold>). In fact, abnormal synchrony of neural oscillations has been reported not only in patients along the clinical spectrum of AD, including mild cognitive impairment (MCI) due to AD and AD-dementia (<bold><italic><xref ref-type="bibr" rid="c28">Jeong, 2004</xref>; <xref ref-type="bibr" rid="c17">Fernández et al., 2006</xref>; <xref ref-type="bibr" rid="c57">Stam et al., 2006</xref>; <xref ref-type="bibr" rid="c29">Koelewijn et al., 2017</xref>; <xref ref-type="bibr" rid="c35">Nakamura et al., 2018</xref>; <xref ref-type="bibr" rid="c23">Hughes et al., 2019</xref>; <xref ref-type="bibr" rid="c40">Ranasinghe et al., 2020</xref>; <xref ref-type="bibr" rid="c33">Meghdadi et al., 2021</xref>; <xref ref-type="bibr" rid="c48">Schoonhoven et al., 2022</xref></italic></bold>) but also during the preclinical stages of AD (<bold><italic><xref ref-type="bibr" rid="c35">Nakamura et al., 2018</xref>; Ranasinghe et al., 2022a</italic></bold>). Neuronal oscillations observed by noninvasive electrophysiological measures, such as electroencephalography (EEG) and magnetoencephalography (MEG), represent the synchronized activity of excitatory and inhibitory neurons and thus provide sensitive indices of altered neuronal and circuit functions in AD. As synaptic dysfunction is strongly associated with AD proteinopathy, altered synchrony of neural oscillations may capture the early functional deficits of neural networks even before clinical symptoms appear. However, it remains unknown which neurophysiological signature changes capture such deficits and the temporal evolution of these changes along the timeline of preclinical to MCI to AD dementia stages in clinical populations.</p>
<p>In this study, we investigated the trajectories of neurophysiological changes along the course of clinical AD progression, by examining long-range and local neural synchrony patterns in the resting brain. We hypothesized that frequency-specific long-range and local synchrony abnormalities in neuronal oscillations may precede both neurodegeneration and cognitive deficits. To examine the temporal relationship amongst altered neural synchrony, neurodegeneration, and cognitive deficits, we used data-driven disease progression models–event-based sequencing models (EBMs), which have been successfully used to predict AD progression from cross-sectional biomarker data (<bold><italic><xref ref-type="bibr" rid="c18">Fonteijn et al., 2012</xref>; <xref ref-type="bibr" rid="c67">Young et al., 2014</xref>, <xref rid="c66" ref-type="bibr">2018</xref></italic></bold>). In an EBM, disease progression is described as a series of discrete events, defined as the occurrence of a particular biomarker reaching a threshold abnormal value, and the estimated likelihood of temporal sequence of events defines the disease trajectory. Modifying the conventional EBMs, to find the neurophysiological trajectories, we developed a robust EBM framework that is less sensitive to abnormal threshold determinants and hence with unbiased subject assignments to disease stages.</p>
<p>We considered two representative neuronal oscillatory synchrony metrics: amplitude-envelope correlation (AEC) and regional spectral power. The AEC and spectral power quantify long-range and local neural synchrony, respectively. Recent test-retest studies of MEG resting-state metrics have revealed that both metrics are highly reliable (<bold><italic><xref ref-type="bibr" rid="c9">Colclough et al., 2016</xref>; Wiesman et al., 2021a</italic></bold>). To evaluate the frequency specificity of neurophysiological trajectories, three canonical frequency bands, delta-theta, alpha, and beta bands, were considered. For a metric of global cognitive ability, we used the mini-mental state examination (MMSE) score. Neurodegeneration, which is related to neuronal loss as well as synaptic loss and synapse dysfunction (<bold><italic><xref ref-type="bibr" rid="c53">Selkoe, 2002</xref>; <xref rid="c56" ref-type="bibr">Spires-Jones and Hyman, 2014</xref></italic></bold>), is detectable as brain atrophy on structural MRI, and therefore we evaluated neurodegeneration as loss of gray matter (GM) volume, specifically volume loss of the parahippocampal gyrus (PHG), extracted from individual T1 MRIs. We first deployed an Atrophy-Cognition EBM (ACEBM) with only the neurodegeneration and cognitive decline measures, and then quantitatively examined metrics of long-range and local synchrony of neuronal oscillations corresponding to each estimated disease stage. Next, we deployed two separate Synchrony-Atrophy-Cognition EBMs (SAC-EBMs) which respectively included long-range or local neural synchrony measures along with PHG volume and global cognition, and investigated how the synchrony metrics stratify AD progression. Consistent with our hypothesis, we found that long-range and local neural synchrony in the alpha and beta bands, but not in the delta-theta band, becomes abnormal at the earliest preclinical stages of AD, preceding both neurodegeneration and cognitive deficits.</p>
</sec>
<sec id="s2">
<title>Materials and methods</title>
<sec id="s2a">
<title>Participants</title>
<p>The present study included 78 patients who met National Institute of Aging–Alzheimer’s Association (NIA-AA) criteria for probable Alzheimer’s disease or MCI due to AD (<bold><italic><xref ref-type="bibr" rid="c32">McKhann et al., 2011</xref>; <xref ref-type="bibr" rid="c3">Albert et al., 2011</xref>; <xref ref-type="bibr" rid="c24">Jack Jr et al., 2018</xref></italic></bold>), and 70 cognitively-unimpaired older adults. All participants were recruited from research cohorts at the UCSF Alzheimer’s Disease Research Center (UCSF-ADRC). The clinical diagnosis of AD patients was established by consensus in a multidisciplinary team; 67 of the 78 patients were confirmed with positive AD biomarkers. The eligibility criteria for the cognitively normal controls included normal cognitive performance, normal MRI, and absence of neurological, psychiatric, or other major medical diseases. The neuropsychological evaluation for each participant was performed by MMSE within an average of 0.48 years (range: −2.83–1.50) and 0.22 years (range: −1.52–1.01) of the MEG evaluation for controls and patients, respectively. A structured caregiver interview was used to assess the clinical dementia rating scale (CDR) in each participant. Informed consent was obtained from all participants or their assigned surrogate decision makers. The study was approved by the Institutional Review Board of the UCSF.</p>
</sec>
<sec id="s2b">
<title>MRI acquisition and analyses</title>
<p>Structural brain images were acquired using a unified MRI protocol on 3T Siemens MRI scanners (MAGNETOM Prisma or 3T TIM Trio) at the Neuroscience Imaging Center (NIC) at UCSF, within an average of 1.05 years (range: −6.91–0.78) and 0.29 years (range: −2.13–1.29) of the MEG evaluation for controls and patients, respectively. The acquired MRI was used to generate the head model for source reconstructions of MEG sensor data and to evaluate GM volumes. The region-based GM volumes corresponding to the 94 anatomical regions included in the automated anatomical labelling 3 (AAL3) atlas (<bold><italic><xref ref-type="bibr" rid="c45">Rolls et al., 2020</xref></italic></bold>) (Appendix 1—table 1) were computed using the Computational Anatomy Toolbox [CAT12 version 12.8.1 (1987)] (<bold><italic><xref ref-type="bibr" rid="c19">Gaser et al., 2022</xref></italic></bold>), which is an extension of SPM12 (<bold><italic><xref ref-type="bibr" rid="c38">Penny et al., 2011</xref></italic></bold>). The regional GM volumes were evaluated by the morphometry pipeline implemented in CAT12 with default parameters. The total intracranial volume (TIV), the sum of all segments classified as gray and white matter, and cerebrospinal fluid, was also calcu-lated for each subject.</p>
</sec>
<sec id="s2c">
<title>Resting-state MEG</title>
<sec id="s2c1">
<title>Data acquisition</title>
<p>Each participant underwent 10–60-minutes resting-state MEG at the UCSF Biomagnetic Imaging Laboratory. MEG was recorded with a 275 channel full head CTF Omega 2000 system (CTF MEG International Services LP, Coquitlam, British Columbia, Canada). Three fiducial coils including nasion and left and right pre-auricular points were placed to localize the position of head relative to sensor array and later coregistered to individual MRI to generate an individualized head shape. Data collection was optimized to minimize head movements within the session and to keep it below 0.5 cm. For analysis, a 10 min continuous recording was selected from each subject lying supine and awake with the eyes closed (sampling rate <italic>f</italic><sub>s</sub> = 600 Hz). From the continuous recordings, we further selected a 1-min continuous segment with minimal artifacts (i.e. minimal excessive scatter at signal amplitude) for each subject.</p>
</sec>
<sec id="s2c2">
<title>Pre-processing</title>
<p>Each 1-min sensor signal was digitally filtered using a bandpass filter of 0.5–55 Hz. The power spectral density (PSD) of each sensor signal was computed, and artifacts were confirmed by visual inspection. Channels with excessive noise within individual subjects were removed prior to the next process. When environmental noises larger than a few <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline1.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula> were observed around 1–5-Hz range in a PSD, the dual signal subspace projection (DSSP) (<bold><italic><xref ref-type="bibr" rid="c49">Sekihara et al., 2016</xref></italic></bold>) with the lead-field vectors computed for each individual subject’s head model was applied to the filtered sensor signal for the removal of the environmental noises. As a parameter, we chose the dimension of pseudosignal subspace <italic>μ</italic> as 50. DSSPs were needed to be applied to thirteen of the total 148 subject’s signals. For the thirteen data, the resulting dimension of the spatio-temporal intersection, i.e., the degree of freedom to be removed, was 3 or 4. We also applied a preconditioned independent component analysis (ICA) (<bold><italic><xref ref-type="bibr" rid="c1">Ablin et al., 2018</xref></italic></bold>) to the signal to identify cardiac components and remove them. In each data set, one or two clear cardiac ICA-component waveforms with approximately 1 Hz rhythms were observed, which were easily identified by visual inspections.</p>
</sec>
<sec id="s2c3">
<title>Atlas-based source reconstruction</title>
<p>Isotropic voxels (5 mm) were generated in a brain region of a template MRI, resulting in 15, 448 voxels within the brain region. The generated voxels were spatially normalized into individual MRI space, and subject-specific magnetic lead field vectors were computed for each voxel with a single-shell model approximation (<bold><italic><xref ref-type="bibr" rid="c36">Nolte, 2003</xref></italic></bold>). The voxels for each subject were indexed to 94 cortical/ sub-cortical regions included in the AAL3 atlas.</p>
<p>Array-gain scalar beamformer (<bold><italic><xref ref-type="bibr" rid="c51">Sekihara et al., 2004</xref></italic></bold>) was applied to the 60-sec cleaned sensor time series to obtain source-localized brain activity at the voxel level, i.e., voxel-level time courses. Lead field vectors were normalized to avoid the center-of-the-head artifact, and a generalized eigenvalue problem was solved to determine the optimal source orientation (<bold><italic><xref ref-type="bibr" rid="c52">Sekihara and Nagarajan, 2008</xref></italic></bold>). The beamformer weights were calculated in the time domain; a data covariance matrix was calculated using a whole 60-sec time series, and a singular value truncation (threshold of 10<sup>−6</sup> × maximum singular value) was performed when inverting the covariance matrix. Ninety-four regional time courses were extracted with alignment with the AAL3 atlas by performing principal component analysis (PCA) across voxel-level time courses within each of the regions and taking a time course of the first principal component. These pre-processing and source reconstructions were performed using in-house Matlab scripts utilizing Fieldtrip toolbox functions (<bold><italic><xref rid="c37" ref-type="bibr">Oosten- veld et al., 2011</xref></italic></bold>). We also used BrainNet Viewer toolbox (<bold><italic><xref ref-type="bibr" rid="c65">Xia et al., 2013</xref></italic></bold>) to obtain brain rendering images of regional MEG metrics and GM atrophy.</p>
</sec>
<sec id="s2c4">
<title>MEG resting-state metrics</title>
<p>Based on the regional time courses derived from MEG, we evaluated two measures of neural synchrony: the amplitude-envelope correlation (AEC) and the spectral power, which describe long-range and local neural synchrony, respectively. Three canonical frequency bands were considered: 2–7 Hz (delta-theta), 8–12 Hz (alpha), and 15–29 Hz (beta) bands (see also Appendix 1—<xref rid="fig1" ref-type="fig">figure 1</xref>).</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Atrophy-cognition EBM staging of AD progression.</title>
<p>(A) Group comparison of PHG volume [unpaired <italic>t</italic>-test: <italic>t</italic>(143) = −9.508; <sup>∗∗∗</sup><italic>p</italic> &lt; 0.001]. The average PHG volume in patients with AD was 7.99 ml ± 0.09, and the average PHG in controls was 9.28 ml ± 0.11. (B) Histogram of PHG volume loss <italic>z</italic>-scores, <italic>z</italic><sub>PHG</sub>. (C) Group comparison of MMSE scores [unpaired <italic>t</italic>-test: <italic>t</italic>(144) = −10.171; <sup>∗∗∗</sup><italic>p</italic> &lt; 0.001]. (D) Histogram of MMSE-decline <italic>z</italic>-scores, <italic>z</italic><sub>MMSE</sub>. (E) The ratio of subjects classified to each stage; blue: Control (CDR 0), orange: MCI due to AD (CDR 0.5), pink: mild AD dementia (CDR 1), and red: moderate AD dementia (CDR 2). (F) Distribution of the stages in the space spanned by PHG volume loss and MMSE score, which was obtained by distinctly assigning each subject to one of the stages with the highest probability. The colors of the dots denote the seven stages. A star symbol denotes weighted means of <italic>z</italic><sub>PHG</sub> and MMSE scores at stage 4: <italic>z</italic><sub>PHG</sub> = 1.33(±0.258) and MMSE= 26.3(±0.82). The values in parentheses denote the standard error (SE; <bold><italic><xref ref-type="disp-formula" rid="eqn5">Equation 5</xref></italic></bold>) of the probability-based weighted means. (G) Trajectories of PHG volume loss and MMSE score as a function of the seven stages. Probability-based weighted means (± SE) are shown. The initial and final <italic>z</italic>-scores used in this AC-EBM were: (<italic>z</italic><sub>initial</sub>, <italic>z</italic><sub>final</sub>) = (−1.372, 3.804) for PHG volume loss and (−0.902, 12.712) for MMSE decline, respectively. (H) Progression of GM volume loss (<italic>z</italic>-scores) from stage 1 to 7. Regional GM atrophy in the MCI stage (stage 4) was circled with dotted lines.</p></caption>
<graphic xlink:href="541379v2_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2c5">
<title>Amplitude-envelope correlation</title>
<p>The AECs is defined as Pearson’s correlations between any two amplitude envelopes of regional time courses (total 94 × 93/2 = 4, 371 pairs). Regional time courses were first processed by a band-pass filtering and then their envelopes were extracted by Hilbert transform. To discount spurious correlations caused by source leakages, we orthogonalized any two band-limited time courses before computing their envelopes by employing a pairwise orthogonalization (<bold><italic><xref ref-type="bibr" rid="c21">Hipp et al., 2012</xref>; <xref rid="c50" ref-type="bibr">Sekihara and Nagarajan, 2015</xref></italic></bold>). The AEC with leakage correction is often expressed as AEC-c and is known as a robust measure (<bold><italic>Briels et al., 2020b</italic></bold>). The pairwise orthogonalization provides asymmetric values between two time courses; the value depends on which time course is taken as a seed. Therefore, Pearson’s correlations between orthogonalized envelopes for both directions were averaged, resulting in a symmetric AEC matrix. Regional AECs, which represent the node degrees, were computed by averaging over row/column components of the symmetric AEC matrix.</p>
</sec>
<sec id="s2c6">
<title>Spectral power</title>
<p>The spectral power of a given band, which has often been used as a metric to discriminate patients with AD from controls (<bold><italic><xref ref-type="bibr" rid="c28">Jeong, 2004</xref>; <xref ref-type="bibr" rid="c16">Engels et al., 2016</xref>; Wiesman et al., 2021b</italic></bold>), is defined by the ratio of a band power to total power and was calculated from regional PSDs. Regional PSDs were calculated from the 94 regional time courses using Welch’s method (50% overlap) with 0.293-Hz (= <italic>f</italic><sub>s</sub>/2048) steps.</p>
</sec>
<sec id="s2c7">
<title>Scalar neural synchrony metrics</title>
<p>To identify general trends in changes in the long-range and local synchrony with the severity of AD, we performed group comparisons of the regional synchrony metrics between AD patients and controls. Based on the group contrasts of regional metrics observed, we introduced scalar synchrony metrics by calculating the averages within several regions where large region-level group contrasts were identified. The scalar MEG metrics were used in the SAC-EBMs.</p>
</sec>
</sec>
<sec id="s2d">
<title>Metric trajectory analyses</title>
<sec id="s2d1">
<title>Event-based sequencing modeling</title>
<p>Imaging and neuropsychological biomarkers for AD are continuous quantities taking values from normal to severe, while the stages of the disease are discrete and are identified by estimating the values of the biomarkers (<bold><italic><xref ref-type="bibr" rid="c55">Sperling et al., 2011</xref></italic></bold>). As a data-driven disease progression model, an event-based sequencing model (EBM) has been proposed that allows us to make inferences about disease progression from cross-sectional data (<bold><italic><xref ref-type="bibr" rid="c18">Fonteijn et al., 2012</xref>; <xref ref-type="bibr" rid="c67">Young et al., 2014</xref>, <xref rid="c66" ref-type="bibr">2018</xref></italic></bold>). In an EBM, disease progression is described as a series of metric events, where events are defined as the occurrences of abnormal values of metrics, and the values of events act as thresholds to determine discrete stages of disease (<bold><italic><xref ref-type="bibr" rid="c18">Fonteijn et al., 2012</xref></italic></bold>). The model infers temporal sequences of the events from cross-sectional data.</p>
<p>It is also possible to set multiple events per metric by defining them as occurrences of taking certain <italic>z</italic>-scores within the range from initial to final <italic>z</italic>-scores ([<italic>z</italic><sub>initial</sub> <italic>z</italic><sub>final</sub>]), in which <italic>z</italic>-scores for each metric linearly increase between all consecutive events and stages are located at temporal midpoints between the two consecutive event occurrence times (<bold><italic><xref ref-type="bibr" rid="c66">Young et al., 2018</xref></italic></bold>). In this linear <italic>z</italic>-score event model, a metric trajectory is described as a series of metric values evaluated at estimated stages.</p>
<p>We developed a robust EBM framework to quantify metric trajectories on the basis of the linear <italic>z</italic>-score model, employing a multivariate-Gaussian-form data likelihood:
<disp-formula id="eqn1">
<alternatives><graphic xlink:href="541379v2_eqn1.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
where a conditional probability, <italic>p</italic>(<italic>Z</italic><sub><italic>j</italic></sub> |<italic>S</italic>, stage(<italic>j</italic>) = <italic>k</italic>), describes the probability that a subject <italic>j</italic> takes biomarker values of <italic>Z</italic><sub><italic>j</italic></sub> given a sequence of events <italic>S</italic> and that stage(<italic>j</italic>) = <italic>k</italic> (i.e. the subject <italic>j</italic> has been in a stage <italic>k</italic>). The probability is proportional to a Gaussian distribution:
<disp-formula id="eqn2">
<alternatives><graphic xlink:href="541379v2_eqn2.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
In <bold><italic><xref ref-type="disp-formula" rid="eqn1">Equation 1</xref></italic></bold>, <italic>N</italic> denotes a total number of events, and <italic>i, j</italic>, and <italic>k</italic> are the indices of metric, subject, and stage, respectively. <italic>J</italic> is the number of subjects (<italic>J</italic> = 148). <italic>I</italic> is the number of metrics: <italic>I</italic> = 2 for an AC-EBM and <italic>I</italic> = 3 for an SAC-EBM, respectively. The symbol <italic>Z</italic><sub><italic>j</italic></sub> = [<italic>z</italic><sub>1<italic>j</italic></sub>, <italic>z</italic><sub>2<italic>j</italic></sub>, …, <italic>z</italic><sub><italic>Ij</italic></sub>]<sup>T</sup>, where <italic>z</italic><sub><italic>ij</italic></sub> denotes the <italic>z</italic>-score of a metric <italic>i</italic> for the subject <italic>j</italic>, and the symbol <italic>Z</italic> = [<italic>Z</italic><sub>1</sub>, <italic>Z</italic><sub>2</sub>, …, <italic>Z</italic><sub><italic>J</italic></sub> ] describing the data matrix with <italic>I</italic> × <italic>J</italic>-dimension. The symbol <italic>μ</italic><sub><italic>i</italic></sub>(<italic>k</italic>) denotes a value of the <italic>k</italic>-th stage of a metric <italic>i</italic> and is given by a linearly interpolated midpoint <italic>z</italic>-score between two <italic>z</italic>-scores evaluated at consecutive event occurrence times. Since there are <italic>N</italic> + 2 event occurrence times including initial and final times, <italic>N</italic> + 1 stages are provided. When employing <bold><italic><xref ref-type="disp-formula" rid="eqn1">Equation 1</xref></italic></bold>, we assumed that the prior distribution is uniform: <italic>p</italic>(stage(<italic>j</italic>) = <italic>k</italic> |<italic>S</italic>) = (<italic>N</italic> + 1)<sup>−1</sup>. A linear <italic>z</italic>-score model and the relationship between a set of events and the estimated stages are illustrated in Appendix 1—<xref rid="fig2" ref-type="fig">figure 2</xref>.</p>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2.</label>
<caption><title>Profiles of neural synchrony as a function of the AD stages estimated by AC-EBM.</title>
<p>(A,B) Profiles of AEC (A) and spectral power (B) as a function of the seven stages, showing probability-based weighted means (± SE). Neural synchrony increased monotonously with AD progression in the delta-theta band and decreased monotonously in the alpha and beta bands. (C,D) Regional AEC (C) and spectral power (D) as a function of the seven stages. Deviations from the neural synchrony spatial patterns averaged over the controls are displayed. The deviations were calculated by using probability-based weighted means of the <italic>z</italic>-scores standardized by the controls. Spatial patterns in the MCI stage (stage 4) were circled with dotted lines. (E,F) Changes in neural synchrony during the preclinical stages. Regional comparisons between two stages (stages 4 vs. 1) are shown based on non-parametric tests of the weighted mean differences <italic>δz</italic>. Differences that exceed the threshold (<italic>q</italic> &lt; 0.05) are displayed. There were no significant differences in long-range synchrony in the delta-theta band.</p></caption>
<graphic xlink:href="541379v2_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>The most likely order of events is given by the sequence of events, <italic>S</italic>, which maximizes the posterior distribution <italic>P</italic> (<italic>S</italic> |<italic>Z</italic>) = <italic>P</italic> (<italic>S</italic>)<italic>P</italic> (<italic>Z</italic> |<italic>S</italic>)/<italic>P</italic> (<italic>Z</italic>). On the assumption that the prior <italic>P</italic> (<italic>S</italic>) is uniformly distributed (<bold><italic><xref ref-type="bibr" rid="c18">Fonteijn et al., 2012</xref></italic></bold>), the most likely sequence is obtained by solving the maximum likelihood problem of maximizing <bold><italic><xref ref-type="disp-formula" rid="eqn1">Equation 1</xref></italic></bold>. To solve the problem, for a given set of events, we performed Markov chain Monte Carlo (MCMC) sampling on sequences (<bold><italic><xref ref-type="bibr" rid="c66">Young et al., 2018</xref></italic></bold>) and chose the maximum likelihood sequence from 50, 000 MCMC samples.</p>
</sec>
<sec id="s2d2">
<title><italic>z</italic>-scoring of metrics</title>
<p>We computed <italic>z</italic>-scores of the PHG volume, MMSE score, and scalar neural synchrony metrics to utilize them in the EBM frameworks. Since a linear <italic>z</italic>-score model assumes a monotonous increase in <italic>z</italic>-scored metrics along disease progression (i.e., higher stage denotes more severity), “sign-inverted” <italic>z</italic>-scores were introduced to the metrics with decreasing trends along disease progression. Specifically, for GM volumes, MMSE score, and neural synchrony metrics in the alpha and beta bands, the <italic>z</italic> score of a metric <italic>i</italic> for a subject <italic>j</italic> was defined by <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline2.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula>, where <italic>x</italic><sub><italic>ij</italic></sub> denotes a value of a metric <italic>i</italic> for a subject <italic>j</italic>, and <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline3.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula> and <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline4.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula> denote the mean and standard deviation (SD) of the metric values of the controls, respectively. For the delta-theta-band neural synchrony metrics, <italic>z</italic>-scores were defined in a standard way as <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline5.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula>. Using these <italic>z</italic>-scored metrics, the initial and final events, <italic>z</italic><sub>initial</sub> and <italic>z</italic><sub>final</sub>, for each metric were set as the bottom and top 10% average <italic>z</italic>-scores, respectively.</p>
</sec>
<sec id="s2d3">
<title>Events-setting optimization</title>
<p>In addition to the initial and final events of the <italic>z</italic>-score, we set three events for each metric because various possible curves of the metric trajectories were supposed to be well expressed by three variable points with two fixed points. For example, in an AC-EBM analysis, that is, a two-metric trajectory analysis for PHG volume loss and MMSE decline, a total of six events were considered (<italic>N</italic> = 6). The metric trajectory as a series of stage values <italic>μ</italic><sub><italic>i</italic></sub>(<italic>k</italic>) is sensitive to event settings because predefined events do not necessarily capture appropriate boundaries between disease stages. To determine disease stages less sensitive to specifications of the <italic>z</italic>-score events, we tried several sets of events and selected the set of events with the largest data likelihood amongst the trials. Specifically, we searched for the set of events that better fit the data <italic>Z</italic> by trying all combinations of three <italic>z</italic>-scores from {0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8}-quantiles for each metric. The number of combinations of events for each metric was accordingly (<sub>7</sub><italic>C</italic><sub>3</sub> =)35. Therefore, MCMC samplings (50, 000 samples for each set of events) were performed 1, 225 times for an AC-EBM and 42, 875 times for an SAC-EBM, respectively, to find the set of events and their sequence <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline6.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula> with the highest data likelihood. This exhaustive search of optimal event settings, which was not implemented in a conventional linear <italic>z</italic>-score EBM (<bold><italic><xref ref-type="bibr" rid="c66">Young et al., 2018</xref></italic></bold>), is diagrammatically shown in Appendix 1—<xref rid="fig2" ref-type="fig">figure 2</xref>.</p>
</sec>
<sec id="s2d4">
<title>Trajectory computations</title>
<p>Given the most likely sequence <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline7.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula> as a result of the exhaustive search, the probabilities that a subject <italic>j</italic> falls into stage <italic>k</italic> are evaluated by the posterior distribution
<disp-formula id="eqn3">
<alternatives><graphic xlink:href="541379v2_eqn3.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
The probabilities, <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline8.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula>, describe the contribution of a subject <italic>j</italic> to stage <italic>k</italic>, which allows us to evaluate a stage value of a metric <italic>i</italic> at stage <italic>k</italic> as a weighted mean:
<disp-formula id="eqn4">
<alternatives><graphic xlink:href="541379v2_eqn4.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
Then, we represented the trajectory of the metric <italic>i</italic> by a series of the stage values, <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline9.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula>. The standard error (SE) of the weighted mean at stage <italic>k</italic> was evaluated by
<disp-formula id="eqn5">
<alternatives><graphic xlink:href="541379v2_eqn5.gif" mimetype="image" mime-subtype="gif"/></alternatives>
</disp-formula>
where σ<sub><italic>i</italic></sub> is a standard deviation of a metric <italic>i</italic>. This definition of SE provides an usual expression of the standard error of the mean, <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline10.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula>, if all subjects contributed equally to stage <italic>k</italic>. These formulations of trajectories were applied to several metrics. In the AC-EBM, the metrics <italic>i</italic> denote the PHG volume loss <italic>z</italic>-score and the MMSE scores. In the SAC-EBM, they denote each scalar neural synchrony metric in addition to the PHG volume loss <italic>z</italic>-score and the MMSE score. We also used <bold><italic><xref ref-type="disp-formula" rid="eqn4">Equation 4</xref></italic></bold> to evaluate the progressions of the regional neural synchrony <italic>z</italic>-scored metrics and the GM volume loss <italic>z</italic>-scores along the estimated EBM stages. When evaluating the ratio of subjects categorized to each stage, we treated (<italic>x</italic><sub><italic>i</italic>1</sub>, <italic>x</italic><sub><italic>i</italic>2</sub>, …, <italic>x</italic><sub><italic>iJ</italic></sub>) as an one-hot vector, where a metric <italic>i</italic> represents a subjects’ category provided by CDR scale. For example, when evaluating the ratio of subject with CDR 0.5, <italic>x</italic><sub><italic>ij</italic></sub> = 1 only when a subject <italic>j</italic> has CDR scale of 0.5, otherwise <italic>x</italic><sub><italic>ij</italic></sub> = 0.</p>
</sec>
</sec>
</sec>
<sec id="s3">
<title>Statistical analyses</title>
<p>To test demographic differences between AD patients and controls, unpaired <italic>t</italic>-test was used for age, and chi-square test was used for sex. Age was defined at the time of the MEG scan date. In the statistical analyses, <italic>p</italic>-values below 0.05 were considered statistically significant. For group comparisons of GM volumes, MMSE scores, and neural synchrony metrics, two-sided significance tests (against a null value of <italic>z</italic>ero) were performed using the general linear model (GLM). For statistical tests on GM volumes, TIV, age, and the difference between MRI and MEG dates were included as covariates. For statistical tests on MMSE scores, age and the difference between the MMSE and MEG dates were included as covariates. For statistical tests on neural synchrony metrics, age was included as a covariate. The problem of multiple comparisons between 94 regions was solved by controlling the Benjamini-Hochberg false discovery rate (FDR) (<bold><italic><xref ref-type="bibr" rid="c4">Benjamini and Hochberg, 1995</xref></italic></bold>). The FDR adjusted <italic>p</italic>-value (i.e. <italic>q</italic>-value) below 0.05 or 0.01 was considered statistically significant.</p>
<p>A nonparametric test was performed to statistically compare metrics between stages, i.e., to test statistical significance of the difference between stage values represented by weighted means [e.g., stage <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline11.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula> ]. For a metric <italic>i</italic>, we used bootstrap resampling (50, 000 samples) of an original data set, <bold><italic>x</italic></bold><sub><italic>i</italic></sub> = (<italic>x</italic><sub><italic>i</italic>1</sub>, <italic>x</italic><sub><italic>i</italic>2</sub>, …, <italic>x</italic><sub><italic>iJ</italic></sub>), to generate new data sets, <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline12.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula>, using a random number generator, where each <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline13.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula> is one of the components in the original data set <bold><italic>x</italic></bold><sub><italic>i</italic></sub>. We then calculated the weighted means <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline14.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula> (<bold><italic><xref ref-type="disp-formula" rid="eqn4">Equation 4</xref></italic></bold>) for each sample. The same procedures were performed for stage <italic>k</italic><sup>′</sup>, obtaining weighted means <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline15.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula> for each sample. We then tested the null hypothesis that a weighted mean in stage <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline16.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula>, is equal to a weighted mean in stage <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline17.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula>, evaluating the null distribution of differences in weighted mean values, <inline-formula><alternatives><inline-graphic xlink:href="541379v2_inline18.gif" mimetype="image" mime-subtype="gif"/></alternatives></inline-formula>. The problem of multiple comparisons across stages was solved by controlling the FDR. The <italic>q</italic>-value below 0.05 was considered statistically significant.</p>
</sec>
<sec id="s4">
<title>Results</title>
<sec id="s4a">
<title>Participant demographics</title>
<p>This study included a cohort of 78 patients with AD (50 female; 28 male) including 35 patients with AD dementia and 43 patients with MCI due to AD. and also included 70 cognitively-unimpaired older adults as controls (41 female; 29 male). The CDR scales were 0 for cognitively-unimpaired controls, 0.5 for patients with MCI, and 1 (<bold><italic>n</italic></bold> = 27) or 2 (<bold><italic>n</italic></bold> = 8) for patients with AD dementia. There was no difference in sex distribution between the AD and control groups [<italic>χ</italic><sup>2</sup>(1) = 0.477; <italic>p</italic> = 0.49]. h higher in the control group than patients with AD (controls, mean±SE: 70.5 ± 0.99, range: 49.5–87.7; AD, mean±SE: 63.9 ± 1.01, range: 49.0–84.4) [unpaired <italic>t</italic>-test: <italic>t</italic>(146) = −4.708; <italic>p</italic> &lt; 0.001]. Average MMSE in patients with AD was 22.7 ± 0.43 (mean±SE) while the average MMSE in the controls 29.2 ± 0.48 (<xref rid="fig1" ref-type="fig"><bold><italic>Figure 1</italic></bold>C, D</xref>).</p>
<p>Group comparisons of GM volumes for each of the anatomical regions included in the AAL3 atlas showed that GM volumes in the temporal regions are significantly smaller in AD patients than in controls (Appendix 1—<xref rid="fig3" ref-type="fig">figure 3</xref>, Appendix 1—table 2). Amongst the temporal GM volumes, we focused on a volume of PHG as a key indicator of neurodegeneration in AD progression. The PHG includes perirhinal and entorhinal cortices of the medial temporal lobe (MTL), and MRI-based studies have reported that the volume of MTL reduces, especially in the perirhinal and entorhinal cortices, in early stages of typical AD (<bold><italic><xref ref-type="bibr" rid="c58">Teipel et al., 2006</xref>; <xref ref-type="bibr" rid="c15">Echávarri et al., 2011</xref>; <xref ref-type="bibr" rid="c31">Matsuda, 2016</xref></italic></bold>). The average PHG volume in patients with AD was siginificantly smaller than in the controls (<xref rid="fig1" ref-type="fig"><bold><italic>Figure 1</italic></bold>A, B</xref>).</p>
<fig id="fig3" position="float" fig-type="figure">
<label>Figure 3.</label>
<caption><title>Trajectories of long-range neural synchrony in delta-theta, alpha, and beta-bands from SAC-EBMs.</title>
<p>(A,E,I) The ratio of subjects classified to each stage. The ratio was evaluated on the basis of the probabilities that each subject is assigned to each of the ten stages. (B,F,J) Trajectories of long-range synchrony, PHG volume loss, and MMSE score as a function of the ten stages, showing probability-based weighted means (± SE). The asterisks (<sup>∗</sup><italic>q</italic> &lt; 0.05 and <sup>∗∗∗</sup><italic>q</italic> &lt; 0.001, FDR corrected) denote statistical significance in comparisons between stages 5 vs. 1. All pairs of stages with significant weighted-mean differences are listed in Appendix 1—table 7. Initial and final <italic>z</italic>-scores of long-range synchrony used in the SAC-EBMs were: (<italic>z</italic><sub>initial</sub>, <italic>z</italic><sub>final</sub>) = (−1.083, 2.811), (−1.542, 1.605), and (−1.624, 1.641) in the delta-theta, alpha, and beta bands, respectively. (C,G,K) Regional AEC along the stages. The deviations from the regional patterns of the control group are displayed. The regional patterns at the onset of the MCI stage were circled with dotted lines. (D,H,L) Changes in regional patterns during the preclinical stages. Regional comparisons between two stages based on nonparametric tests of weighted mean differences <italic>δz</italic> are shown. Differences exceeding threshold (<italic>q</italic> &lt; 0.05, FDR corrected) are displayed. The top 10 regions with significant differences are listed in Appendix 1—table 8.</p></caption>
<graphic xlink:href="541379v2_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s4b">
<title>Abnormal frequency specific long-range and local neural synchrony in AD</title>
<p>For regional long-range synchrony (AEC), increases in delta-theta-band synchrony in patients with AD were identified in frontal regions, and reductions in alpha- and beta-band synchrony were identified in the whole brain (Appendix 1—<xref rid="fig4" ref-type="fig">figure 4C, E</xref>; Appendix 1—table 3). These regional contrasts were similar to those observed between AD dementia and subjective cognitive decline (SCD) in MEG/EEG studies (<bold><italic><xref ref-type="bibr" rid="c48">Schoonhoven et al., 2022</xref>; Briels et al., 2020a</italic></bold>). For regional local synchrony (spectral power), increases in delta-theta-band power in patients with AD were identified in the whole brain, and reductions in alpha- and beta-band power were identified in temporal regions and the whole brain, respectively (Appendix 1—<xref rid="fig4" ref-type="fig">figure 4D, F</xref>; Appendix 1—table 4). These regional contrasts were similar to those observed between MCI and controls in an MEG multicenter study (<bold><italic><xref ref-type="bibr" rid="c23">Hughes et al., 2019</xref></italic></bold>).</p>
<fig id="fig4" position="float" fig-type="figure">
<label>Figure 4.</label>
<caption><title>Trajectories of local neural synchrony in delta-theta, alpha and beta bands from SAC-EBMs.</title>
<p>(A,E,I) The ratio of subjects classified to each stage. (B,F,J) Trajectories of local synchrony, PHG volume loss, and MMSE score as a function of the 10 stages, showing the weighted mean (± SE). Asterisks (<sup>∗∗∗</sup><italic>q</italic> &lt; 0.001, FDR corrected) denote statistical significance in comparisons between stages 6 vs. 1. All pairs of stages with significant weighted-mean differences are listed in Appendix 1—table 9. Initial and final z-scores of local synchrony used in the SAC-EBMs were: (z<sub>initial</sub>, z<sub>final</sub>) = (−1.329, 6.097), (−1.461, 2.866), and (−1.810, 2.784) in the delta-theta, alpha, and beta bands, respectively. (C,G,K) Regional spectral power along the stages. Departures from the regional patterns of the control group are shown. The regional patterns at the onset of the MCI stages were circled with dotted lines. (D,H,L) Changes in regional patterns during the preclinical stages. Regional comparisons between two stages are shown based on nonparametric tests of weighted mean differences δz. Differences exceeding threshold (<italic>q</italic> &lt; 0.05, FDR corrected) are displayed. The top 10 regions with significant differences are shown in Appendix 1—table 10.</p></caption>
<graphic xlink:href="541379v2_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Based on the group contrasts of regional metrics observed, we introduced six scalar metrics to quantify long-range and local synchrony: [i] frontal delta-theta-band AEC, [ii] whole-brain alpha-band AEC, [iii] whole-brain beta-band AEC, [iv] whole-brain delta-theta-band spectral power, [v] temporal alpha-band spectral power, and [vi] whole-brain beta-band spectral power. We computed the average within several regions where large region-level group contrasts were identified (the temporal and frontal regions of interest are illustrated in Appendix 1—figure 5). Consistent with the regional-level group comparisons, the long-range and local synchrony scalar metrics in the delta theta band were increased in AD patients compared to controls, and the long-range and local synchrony scalar metrics in the alpha and beta bands were reduced in AD patients compared to controls (Appendix 1—<xref rid="fig4" ref-type="fig">figure 4A, B</xref>). We also calculated the <italic>z</italic> scores, <italic>z</italic><sub>MEG</sub>, of each scalar metric that were used in the SAC-EBMs.</p>
</sec>
<sec id="s4c">
<title>PHG volume loss precedes the MMSE decline in AD progression</title>
<p>An AC-EBM analysis with the two metrics, PHG volume loss, <italic>z</italic><sub>PHG</sub>, and MMSE decline, <italic>z</italic><sub>MMSE</sub>, was performed for six events (<italic>N</italic> = 6; three events for each metric). Robust event thresholds were determined by the exhaustive search of multiple event thresholds (<italic>z</italic>-score thresholds) and choosing the set of event thresholds that maximize the data likelihood (<bold><italic><xref ref-type="disp-formula" rid="eqn1">Equation 1</xref></italic></bold>). The AC-EBM provided seven stages, each located between consecutive event occurrence times. Based on the probabilities that each subject is assigned to each of the seven stages, the ratio of subjects classified to each stage was calculated (<xref rid="fig1" ref-type="fig"><bold><italic>Figure 1</italic></bold>E</xref>). The ratio of subjects with CDR 0.5 was highest at stage 4, and the ratio of controls with CDR 0 at stage 4 was small compared to those in less severe stages of 1–3, indicating that stage 4 corresponds best to clinical MCI due to AD.</p>
<p>The trajectory of PHG volume loss preceded that of MMSE decline (<xref rid="fig1" ref-type="fig"><bold><italic>Figure 1</italic></bold>G</xref>), consistent with the relationship between brain atrophy and cognitive decline described in a hypothetical model of biomarker trajectories (<bold><italic><xref ref-type="bibr" rid="c26">Jack Jr et al., 2010</xref>; <xref ref-type="bibr" rid="c55">Sperling et al., 2011</xref></italic></bold>). <xref rid="fig1" ref-type="fig"><bold><italic>Figure 1</italic></bold>F</xref> visualizes the distribution of the seven stages in the PHG volume loss versus MMSE score. At stage 4, the value of <italic>z</italic><sub>PHG</sub> of 1.33 ± 0.258 was in the range of 1–2. This <italic>z</italic>-score range of PHG volume loss corresponds to a mild-atrophy range representing approximately MCI stage, e.g., in the voxel-based specific regional analysis system for Alzheimer’s disease (VSRAD) software (<bold><italic><xref ref-type="bibr" rid="c22">Hirata et al., 2005</xref>; <xref ref-type="bibr" rid="c30">Matsuda et al., 2012</xref></italic></bold>). Furthermore, the MMSE score of 26.3 ± 0.82 at stage 4 was in the range of 23–27. This range of MMSE scores is considered to be typical for MCI due to AD (<bold><italic><xref ref-type="bibr" rid="c61">Tsoi et al., 2015</xref></italic></bold>). Stage 4 therefore corresponds to MCI stage, whereas stages 3 and 5 correspond to preclinical-AD and mild AD-dementia stages, respectively.</p>
<p>The GM volume <italic>z</italic>-scores as a function of the seven stages showed that prominent atrophy with <italic>z</italic> &gt; 1 is observed in the temporal regions starting at stage 4 (<xref rid="fig1" ref-type="fig"><bold><italic>Figure 1</italic></bold>H</xref>). This trajectory of GM volume approximated the evolution of brain atrophy in the typical progression of AD reported in MRI-based studies; GM volume loss in AD starts in the MTL in the MCI stage, spreads to the lateral temporal and parietal lobes in the mild AD-dementia stage, and spreads further to the frontal lobe in moderate AD-dementia (<bold><italic><xref ref-type="bibr" rid="c47">Scahill et al., 2002</xref>; <xref ref-type="bibr" rid="c60">Tondelli et al., 2012</xref>; <xref ref-type="bibr" rid="c25">Jack Jr et al., 2013</xref></italic></bold>).</p>
<p>These results of the AC-EBM indicate that the PHG volume loss precedes the MMSE decline, and their metric changes track the stages of AD from preclinical AD to moderate AD-dementia. The order of events for GM volume loss and cognitive decline was consistent with the observation that cognitive decline in the early stage of AD progression reflects neuronal loss in the medial temporal regions (<bold><italic><xref ref-type="bibr" rid="c24">Jack Jr et al., 2018</xref>; <xref ref-type="bibr" rid="c13">DeTure and Dickson, 2019</xref></italic></bold>).</p>
</sec>
<sec id="s4d">
<title>Neural synchrony progressively changes throughout AD stages estimated by ACEBM</title>
<p>For the seven stages determined by the AC-EBM (<xref rid="fig1" ref-type="fig"><bold><italic>Figure 1</italic></bold>E–H</xref>), profiles of long-range and local neural synchrony were estimated (<bold><italic><xref rid="fig2" ref-type="fig">Figure 2</xref></italic></bold>). Along the EBM stages, the delta-theta-band synchrony was consistently increased and the alpha and beta-band synchrony was consistently decreased. Neural synchrony showed prominent changes around stage 4 (clinical stage of MCI due to AD). Alpha- and beta-band long-range synchrony decreased steadily across stages 1–3 and then decreased further in stage 4 (<xref rid="fig2" ref-type="fig"><bold><italic>Figure 2</italic></bold>A</xref>). Beta-band local synchrony also decreased by half from 1 to 4 (<xref rid="fig2" ref-type="fig"><bold><italic>Figure 2</italic></bold>B</xref>). In contrast, there were little changes in delta-theta-band long-range synchrony and delta-theta and alpha-band local synchrony from stage 1 to 3 but these changes became prominent after stage 3.</p>
<p>Regional patterns of long-range and local synchrony as a function of the seven stages indicated that prominent changes manifeste at stage 4 (<xref rid="fig2" ref-type="fig"><bold><italic>Figure 2</italic></bold>E, F</xref>; Appendix 1—table 5 and Appendix 1— table 6). The regions with prominent deviations overlapped with the regions where significant increase and decrease in the neural synchrony were observed in the group comparisons (Appendix 1—<xref rid="fig4" ref-type="fig">figure 4E, F</xref>).</p>
<p>The changing patterns of neural synchrony metrics with AD progression indicate that neural synchrony are sensitive indicators of functional change along the AD progression. To further investigate the temporal association of functional deficits with neurodegeneration and cognitive decline, we included neural synchrony in addition to the PHG volume loss and MMSE decline into the EBM frameworks, performing SAC-EBMs.</p>
</sec>
<sec id="s4e">
<title>Long-range synchrony changes in the alpha and beta bands precede PHG volume loss and MMSE decline</title>
<p>SAC-EBMs that include PHG volume loss, <italic>z</italic><sub>PHG</sub>, MMSE decline, <italic>z</italic><sub>MMSE</sub>, and long-range synchrony metric <italic>z</italic>-scores, <italic>z</italic><sub>MEG</sub>, were performed setting a total of nine events (<italic>N</italic> = 9). SAC-EBMs separately included long-range neural synchrony metrics in the delta-theta, alpha, and beta bands. Each EBM determined the order of nine events, thus defining ten stages (Appendix 1—figure 6).</p>
<p>For all frequency bands, around stages 5 and 6, the weighted means of PHG volume loss <italic>z</italic>-scores were in the range of 1–2 and the MMSE scores were in the range of 23–27 (<xref rid="fig3" ref-type="fig"><bold><italic>Figure 3</italic></bold>B, F, J</xref>). Furthermore, the ratio of subjects with CDR 0.5 was large around stage 5 (<xref rid="fig3" ref-type="fig"><bold><italic>Figure 3</italic></bold>A, E, I</xref>). These indicated that stage 5 best represents the onset of clinical MCI stage, and stages 1-4, where MMSE scores remain almost constant at or near 30, correspond to the preclinical stages of AD. The changes in long-range synchrony during the preclinical stages are shown as statistical bars, and the region-level changes are shown in <xref rid="fig3" ref-type="fig"><bold><italic>Figure 3</italic></bold>C–D, G–H</xref>, and <xref ref-type="fig" rid="fig3">K–L</xref>.</p>
<p>Long-range synchrony in the alpha and beta bands decreased markedly during the preclinical stages of AD, preceding both PHG volume loss and MMSE decline. Specifically, between stages 1 and 4, the alpha- and beta-band long-range synchrony decreased by more than 80 % of the total drop seen from stage 1 to 10. The whole brain regions, but especially the temporal regions, were involved in these prominent preclinical changes (<xref rid="fig3" ref-type="fig"><bold><italic>Figure 3</italic></bold>H, L</xref>). In contrast, the trajectory of delta-theta-band long-range synchrony (<xref rid="fig3" ref-type="fig"><bold><italic>Figure 3</italic></bold>B, C</xref>) was almost identical to the evolution of PHG volume loss throughout the stages, but a large variation occurred around the MCI stages (stages 5 and 6) as was found in the AC-EBM (<xref rid="fig2" ref-type="fig"><bold><italic>Figure 2</italic></bold>A</xref>). There were no significant synchrony region-level increases in delta-theta band during preclinical stages (<xref rid="fig3" ref-type="fig"><bold><italic>Figure 3</italic></bold>D</xref>), consistent with an observation seen in the AC-EBM (<xref rid="fig2" ref-type="fig"><bold><italic>Figure 2</italic></bold>F</xref>).</p>
<p>The trajectory shapes of the PHG volume loss (almost linear) and MMSE scores (half parabola) were similar to those obtained in the AC-EBM (<xref rid="fig1" ref-type="fig"><bold><italic>Figure 1</italic></bold>G</xref>). This indicates that prominent changes in alpha- and beta-band long-range synchrony during preclinical stages can be utilized to stratify the preclinical stages determined only by neurodegeneration and cognitive deficits.</p>
</sec>
<sec id="s4f">
<title>Local synchrony changes in the alpha and beta bands precede PHG volume loss and MMSE decline</title>
<p>SAC-EBMs including PHG volume loss, MMSE decline, and local synchrony metric <italic>z</italic>-scores were performed, separately considering delta-theta-, alpha-, and beta-band local synchrony metrics. When considering delta-theta and alpha bands, around stages 6 and 7, the PHG volume loss <italic>z</italic>-scores were in the range of 1–2 and the MMSE scores were in the range of 23–27 (<xref rid="fig4" ref-type="fig"><bold><italic>Figure 4</italic></bold>B, F</xref>), indicating that stage 6 best represents the onset of the MCI stage. Furthermore, the ratios of the subjects with CDR 0.5 were high in stages 6 and 7 (<xref rid="fig4" ref-type="fig"><bold><italic>Figure 4</italic></bold>A, E</xref>). For the beta band, based on similar observations, stage 6 best represented the MCI stage (<xref rid="fig4" ref-type="fig"><bold><italic>Figure 4</italic></bold>I, J</xref>). For all frequency bands, stages 1-5, where MMSE scores remain almost constant at or near 30, corresponded to the preclinical stages of AD. The changes in local synchrony during the preclinical stages are shown as statistical bars, and the corresponding region-level changes are shown in <xref rid="fig4" ref-type="fig"><bold><italic>Figure 4</italic></bold>C–D, G–H</xref>, and <xref ref-type="fig" rid="fig4">K–L</xref>.</p>
<p>Local synchrony in the alpha and beta bands decreased during the preclinical stages of AD, preceding both PHG volume loss and MMSE decline (<xref rid="fig4" ref-type="fig"><bold><italic>Figure 4</italic></bold>F, G</xref> and <xref rid="fig4" ref-type="fig"><bold><italic>Figure 4</italic></bold>J, K</xref>). On the contrary, local synchrony in the delta-theta band increased, lagging the evolution of PHG volume loss (<bold><italic>Fig- ure 4</italic></bold>B, C). Specifically, the alpha-band local synchrony decreased considerably by the onset of the MCI stage, showing significant reductions in the temporal regions (<xref rid="fig4" ref-type="fig"><bold><italic>Figure 4</italic></bold>H</xref>) during the preclinical stages (stages 6 vs 1). It is noted that these trends were inconsistent with those found in the AC-EBM (<xref rid="fig2" ref-type="fig"><bold><italic>Figure 2</italic></bold>B</xref>), especially within the preclinical stages, where there was little change found in the alpha-band local synchrony. This can be interpreted as evidence that early stages in AD progression may be better characterized by including neurophysiological markers as AD indicators. Beta-band local synchrony also decreased during preclinical stages, preceding PHG volume loss and MMSE decline; by stage 5, the beta-band power decreased by approximately 55 % of the total drop seen throughout the stages, and the reductions were observed in the whole brain (<bold><italic><xref rid="fig4" ref-type="fig">Figure 4</xref></italic></bold>L). In contrast to the local synchrony trajectories in the alpha and beta bands, the local synchrony in the delta-theta band increased and the <italic>hyper-</italic>synchrony lagged the evolution of the loss of PHG volume in the preclinical stages and made a large jump around the stages 6 and 7 (<xref rid="fig4" ref-type="fig"><bold><italic>Figure 4</italic></bold>D</xref>).</p>
<p>As shown in the previous section, large alpha- and beta-band <italic>hypo-</italic>synchrony during the preclinical stages was also observed in long-range synchrony (<xref rid="fig3" ref-type="fig"><bold><italic>Figure 3</italic></bold>F, J</xref>). Notably, the decreases in the long-range metrics were much greater than those in the local metrics, especially in the early stages during the phase of the preclinical AD (stages 1–3).</p>
</sec>
</sec>
<sec id="s5">
<title>Discussion</title>
<p>We demonstrated that functional deficits of frequency-specific neural synchrony show progressive changes across AD stages. Both long-range and local neural synchrony in the alpha and beta bands, but not in the delta-theta band, was found to decrease in preclinical stages of AD, preceding neurodegeneration and cognitive decline, with more robust findings for long-range neural synchrony. These findings highlight the frequency-specific manifestations of neural synchrony in AD and that synchrony reductions in the alpha and beta bands are sensitive indices reflecting functional deficits in the earliest stages of disease progression.</p>
<sec id="s5a">
<title>Electrophysiological metrics of neural synchrony precede volume loss and cognitive decline</title>
<p>A key finding from the current study is that functional deficits as depicted by reduced neural synchrony precede structural volume loss and cognitive deficits. The EBMs on cross-sectional data clearly demonstrated that alpha- and beta-band synchrony within the inferior temporal and posterior parieto-occipital regions show significant deficits in the early disease stages–stages where volumetric and clinical deficits are still not significantly deviated from their baseline trajectory. This is consistent with the finding that functional changes occur earlier in the time course than structural changes in AD (<bold><italic><xref ref-type="bibr" rid="c26">Jack Jr et al., 2010</xref>; <xref ref-type="bibr" rid="c55">Sperling et al., 2011</xref></italic></bold>).</p>
<p>Previous functional MRI studies have demonstrated disrupted connectivity especially between the hippocampus and several cortical default mode network (DMN) areas in subjects with amyloid deposition but without cognitive impairment (<bold><italic><xref ref-type="bibr" rid="c54">Sperling et al., 2014</xref></italic></bold>). Such a disruption in the DMN has also been observed in clinically normal older individuals without prominent brain atrophy in MTL preserving hippocampal activity (<bold><italic><xref ref-type="bibr" rid="c34">Miller et al., 2008</xref>; <xref ref-type="bibr" rid="c20">Hedden et al., 2009</xref></italic></bold>), indicating altered functional connectivity during the period of preclinical AD. In contrast to fMRI data reflecting the cascade of neural, metabolic, hemodynamic events in AD, our findings from MEG, which captures the synaptic physiology as the collective oscillatory spectra, demonstrate direct observations of AD-related altered neuronal activity.</p>
</sec>
<sec id="s5b">
<title>Frequency-specific manifestations of neural synchrony deficits along the progression of the disease</title>
<p>We demonstrated that the oscillatory deficits and their temporal association to neurodegeneration and cognitive decline are frequency specific. In particular, it is alpha and beta hyposynchrony that precedes PHG atrophy and MMSE decline, whereas delta-theta hypersynchrony does not seem to show such precedence. This is consistent with previous findings that alpha and beta hyposynchrony is more tightly associated with tau accumulation which is closely allied to neurodegeneration and cognitive decline (<bold><italic><xref ref-type="bibr" rid="c39">Pusil et al., 2019</xref>; <xref ref-type="bibr" rid="c40">Ranasinghe et al., 2020</xref>, <xref ref-type="bibr" rid="c43">2021</xref></italic></bold>). Neural hyposynchrony in the alpha and beta bands may represent harbingers of altered synaptic physiology associated with tau accumulation. In fact, in human postmortem studies, the strongest correlate of cognitive deficits in AD patients is loss of synapse (<bold><italic><xref ref-type="bibr" rid="c12">DeKosky and Scheff, 1990</xref>; <xref ref-type="bibr" rid="c59">Terry et al., 1991</xref></italic></bold>). A study using transgenic AD mice has also shown that synaptotoxicity is an early phenomenon in AD pathophysiology (<bold><italic><xref ref-type="bibr" rid="c68">Zhou et al., 2017</xref></italic></bold>). In the context of fluid biomarkers to detect plasma amyloid, alpha and beta hyposynchrony may detect and quantify tau-associated neurodegenerative mechanisms and hence may provide crucial information for early therapeutic interventions.</p>
<p>Previous studies have also shown that delta-theta oscillatory activity is increased in AD and is strongly associated with amyloid accumulation (<bold><italic><xref ref-type="bibr" rid="c40">Ranasinghe et al., 2020</xref>, 2022b</italic></bold>). In particular, increased delta-theta activity is a robust signal in individuals who are amyloid positive and cognitively unimpaired as well as those who harbor APOE-<italic>ϵ</italic>4 allele and an increased risk of AD (<bold><italic><xref ref-type="bibr" rid="c11">Cuesta et al., 2015</xref>; <xref ref-type="bibr" rid="c35">Nakamura et al., 2018</xref></italic></bold>). These previous findings indicate that delta-theta hypersynchrony is an early change in AD spectrum and may even precede the neurodegeneration and cognitive deficits. However, in the current results, the trajectory of the delta-theta hypersynchrony was identical to or lagged that of the PHG volume loss. This apparent controversy may be due to the possibility that oscillatory changes in the delta-theta band are more closely related to amyloid accumulations in AD, which become saturated early in the disease course and have a poor association with neurodegeneration and cognitive trajectories. It would be worth exploring how the trajectory of early saturated variables may be captured by EBM approaches.</p>
</sec>
<sec id="s5c">
<title>Distinction between long-range and local synchrony deficits in disease progression</title>
<p>The decrease in alpha and beta-band long-range metrics in the preclinical stages was much greater than that in the local metrics. This is consistent with the fact that AD-related abnormal brain activities are observed as disruptions of functional networks. Long-range cross-regional metrics, such as AECs, directly capture network disruptions involving all brain regions, while local metrics capture features of individual regions. From the definition, local synchrony describes collective neuronal oscillations in each local region, and thus the change along AD progression may depend mainly on long-term, slowly changing regional neuronal loss. On the other hand, long-range synchrony describes temporal coherence amongst regional collective neuronal oscillations and is vulnerable to altered neuronal oscillations. Therefore, long-range metrics are more sensitive to abnormal rhythms, gathering local abnormalities.</p>
<p>Preclinical neurophysiological markers that indicate the pathophysiology of AD are clinically important but have not been established. A<italic>β</italic> accumulation in preclinical stages is just a necessary condition for AD, and additional preclinical markers are required to fully predict the progression of AD. From this point of view, the present study indicates that alpha and beta-band MEG metrics, especially long-range-synchrony metrics (AEC), which were found to be sensitive to preclinical stages, might be promising candidates as such additional markers.</p>
</sec>
<sec id="s5d">
<title>Limitations</title>
<p>A limitation of the current study is that there were differences in age between controls and AD patients. Although we adjusted the age of each metric employing GLMs, age trajectories in neurophysiological measures have been reported to be nonlinear even in healthy aging (<bold><italic><xref ref-type="bibr" rid="c46">Sahoo et al., 2020</xref></italic></bold>). Age-related changes in brain atrophy have also been reported to follow a nonlinear time course depending on the brain areas (<bold><italic><xref ref-type="bibr" rid="c10">Coupé et al., 2019</xref></italic></bold>). These studies indicate that it may be better to employ a non-linear method beyond GLM to perfectly correct aging effects.</p>
<p>Another limitation is that we have not examined the heterogeneity in AD progression although we clarified for the first time the time courses of MEG neurophysiological metrics in AD progression. In fact, AD is a heterogeneous multifactorial disorder with various pathobiological subtypes (<bold><italic><xref ref-type="bibr" rid="c27">Jellinger, 2022</xref></italic></bold>). In this context, an EBM called <italic>Subtype and Stage Inference</italic> (SuStaIn) capable of capturing spatio-temporal heterogeneity of diseases (<bold><italic><xref ref-type="bibr" rid="c66">Young et al., 2018</xref></italic></bold>) has been proposed for subtyping of neurodegenerative diseases including typical AD and has been applied to find different spatio-temporal trajectories of longitudinal tau-PET data in AD (<bold><italic><xref ref-type="bibr" rid="c62">Vogel et al., 2021</xref></italic></bold>). Since oscillatory rhythms are thought to depend on AD subtypes (<bold><italic><xref ref-type="bibr" rid="c41">Ranasinghe et al., 2017</xref>, 2022a</italic></bold>), an extended trajectory analysis considering both spatial and temporal variations of MEG/EEG metrics is warranted in the future and such analyses would provide distinct neurophysiological trajectories depending on AD subtypes.</p>
</sec>
</sec>
<sec id="d1e1925" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material id="d1e2032">
<label>Supplementary Figures and Tables</label>
<media xlink:href="supplements/541379_file02.pdf"/>
</supplementary-material>
</sec>
</body>
<back>
<sec id="s6">
<title>Data availability</title>
<p>The informed consent did not include a declaration regarding the public availability of the data, and the data for this study will not be made publicly available. Anonymized data may be shared on request from qualified investigators for the purposes of replicating procedures and results within the limits of participants’ consent. Matlab scripts used in this study are available from the corresponding author upon reasonable requests.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>The authors thank all study participants for their support for our research.</p>
</ack>
<sec id="s7">
<title>Funding</title>
<p>This study was supported by the following grants: the National Institutes of Health grants: R01AG062196 (S.S.N.), R01NS100440 (S.S.N.), R01DC017091 (S.S.N.), P50DC019900 (S.S.N.), P30AG062422 (G.D.R., B.L.M.), K23AG038357 (K.V.), K08AG058749 (K.G.R.), R21AG077498 (K.G.R.); University of California grant: UCOP-MRP-17-454755 (S.S.N); John Douglas French Alzheimer’s Foundation (K.V.); S.D. Bechtel Jr. Foundation (K.V.); Alzheimer’s Association grant: PCTRB-13-288476 mmade possible by Part the Cloud™ (K.V.), AARG-21-849773 (K.G.R.); Larry L. Hillblom Foundation grant: 2015-A-034-FEL (K.G.R.); Larry L. Hillblom Foundation grant: 2019-A-013-SUP (KGR); Research contract from Ricoh MEG Inc (S.S.N., H.E.K.).</p>
</sec>
<sec id="s8">
<title>Competing interests</title>
<p>K.K. and H.M. are employees of Ricoh Company, Ltd. The authors declare that no other competing interests exist. The other authors declare no competing financial conflicts of interest to disclose.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><mixed-citation publication-type="journal"><string-name><surname>Ablin</surname> <given-names>P</given-names></string-name>, <string-name><surname>Cardoso</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Gramfort</surname> <given-names>A.</given-names></string-name> <article-title>Faster independent component analysis by preconditioning with Hessian approximations</article-title>. <source>IEEE Transactions on Signal Processing</source>. <year>2018</year>; <volume>66</volume>(<issue>15</issue>):<fpage>4040</fpage>–<lpage>4049</lpage>.</mixed-citation></ref>
<ref id="c2"><mixed-citation publication-type="journal"><string-name><surname>Ahnaou</surname> <given-names>A</given-names></string-name>, <string-name><surname>Moechars</surname> <given-names>D</given-names></string-name>, <string-name><surname>Raeymaekers</surname> <given-names>L</given-names></string-name>, <string-name><surname>Biermans</surname> <given-names>R</given-names></string-name>, <string-name><surname>Manyakov</surname> <given-names>N</given-names></string-name>, <string-name><surname>Bottelbergs</surname> <given-names>A</given-names></string-name>, <string-name><surname>Wintmolders</surname> <given-names>C</given-names></string-name>, <string-name><surname>Van Kolen</surname> <given-names>K</given-names></string-name>, <string-name><surname>Van De Casteele</surname> <given-names>T</given-names></string-name>, <string-name><surname>Kemp</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Drinkenburg</surname> <given-names>WH</given-names></string-name>. <article-title>Emergence of early alterations in network oscillations and functional connectivity in a tau seeding mouse model of Alzheimer’s disease pathology</article-title>. <source>Scientific Reports</source>. <year>2017</year>; <volume>7</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>14</lpage>.</mixed-citation></ref>
<ref id="c3"><mixed-citation publication-type="journal"><string-name><surname>Albert</surname> <given-names>MS</given-names></string-name>, <string-name><surname>DeKosky</surname> <given-names>ST</given-names></string-name>, <string-name><surname>Dickson</surname> <given-names>D</given-names></string-name>, <string-name><surname>Dubois</surname> <given-names>B</given-names></string-name>, <string-name><surname>Feldman</surname> <given-names>HH</given-names></string-name>, <string-name><surname>Fox</surname> <given-names>NC</given-names></string-name>, <string-name><surname>Gamst</surname> <given-names>A</given-names></string-name>, <string-name><surname>Holtzman</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Jagust</surname> <given-names>WJ</given-names></string-name>, <string-name><surname>Petersen</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Snyder</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Carrillo</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Thies</surname> <given-names>B</given-names></string-name>, <string-name><surname>Phelps</surname> <given-names>CH</given-names></string-name>. <article-title>The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease</article-title>. <source>Alzheimer’s &amp; Dementia</source>. <year>2011</year>; <volume>7</volume>(<issue>3</issue>):<fpage>270</fpage>–<lpage>279</lpage>.</mixed-citation></ref>
<ref id="c4"><mixed-citation publication-type="journal"><string-name><surname>Benjamini</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Hochberg</surname> <given-names>Y.</given-names></string-name> <article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source>Journal of the Royal statistical society: series B (Methodological)</source>. <year>1995</year>; <volume>57</volume>(<issue>1</issue>):<fpage>289</fpage>–<lpage>300</lpage>.</mixed-citation></ref>
<ref id="c5"><mixed-citation publication-type="journal"><string-name><surname>Briels</surname> <given-names>CT</given-names></string-name>, <string-name><surname>Schoonhoven</surname> <given-names>DN</given-names></string-name>, <string-name><surname>Stam</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>de Waal</surname> <given-names>H</given-names></string-name>, <string-name><surname>Scheltens</surname> <given-names>P</given-names></string-name>, <string-name><surname>Gouw</surname> <given-names>AA</given-names></string-name>. <article-title>Reproducibility of EEG functional connectivity in Alzheimer’s disease</article-title>. <source>Alzheimer’s Research &amp; Therapy</source>. <year>2020</year>; <volume>12</volume>:<fpage>1</fpage>–<lpage>14</lpage>.</mixed-citation></ref>
<ref id="c6"><mixed-citation publication-type="journal"><string-name><surname>Briels</surname> <given-names>CT</given-names></string-name>, <string-name><surname>Stam</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Scheltens</surname> <given-names>P</given-names></string-name>, <string-name><surname>Bruins</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lues</surname> <given-names>I</given-names></string-name>, <string-name><surname>Gouw</surname> <given-names>AA</given-names></string-name>. <article-title>In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer’s disease</article-title>. <source>Clinical Neurophysiology</source>. <year>2020</year>; <volume>131</volume>(<issue>1</issue>):<fpage>88</fpage>–<lpage>95</lpage>.</mixed-citation></ref>
<ref id="c7"><mixed-citation publication-type="journal"><string-name><surname>Busche</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Eichhoff</surname> <given-names>G</given-names></string-name>, <string-name><surname>Adelsberger</surname> <given-names>H</given-names></string-name>, <string-name><surname>Abramowski</surname> <given-names>D</given-names></string-name>, <string-name><surname>Wiederhold</surname> <given-names>KH</given-names></string-name>, <string-name><surname>Haass</surname> <given-names>C</given-names></string-name>, <string-name><surname>Staufenbiel</surname> <given-names>M</given-names></string-name>, <string-name><surname>Konnerth</surname> <given-names>A</given-names></string-name>, <string-name><surname>Garaschuk</surname> <given-names>O.</given-names></string-name> <article-title>Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer’s disease</article-title>. <source>Science</source>. <year>2008</year>; <volume>321</volume>(<issue>5896</issue>):<fpage>1686</fpage>–<lpage>1689</lpage>.</mixed-citation></ref>
<ref id="c8"><mixed-citation publication-type="journal"><string-name><surname>Busche</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Wegmann</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dujardin</surname> <given-names>S</given-names></string-name>, <string-name><surname>Commins</surname> <given-names>C</given-names></string-name>, <string-name><surname>Schiantarelli</surname> <given-names>J</given-names></string-name>, <string-name><surname>Klickstein</surname> <given-names>N</given-names></string-name>, <string-name><surname>Kamath</surname> <given-names>TV</given-names></string-name>, <string-name><surname>Carlson</surname> <given-names>GA</given-names></string-name>, <string-name><surname>Nelken</surname> <given-names>I</given-names></string-name>, <string-name><surname>Hyman</surname> <given-names>BT</given-names></string-name>. <article-title>Tau impairs neural circuits, dominating amyloid-β effects, in Alzheimer models in vivo</article-title>. <source>Nature Neuroscience</source>. <year>2019</year>; <volume>22</volume>(<issue>1</issue>):<fpage>57</fpage>–<lpage>64</lpage>.</mixed-citation></ref>
<ref id="c9"><mixed-citation publication-type="journal"><string-name><surname>Colclough</surname> <given-names>GL</given-names></string-name>, <string-name><surname>Woolrich</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Tewarie</surname> <given-names>P</given-names></string-name>, <string-name><surname>Brookes</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Quinn</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>SM</given-names></string-name>. <article-title>How reliable are MEG resting-state connectivity metrics?</article-title> <source>Neuroimage</source>. <year>2016</year>; <volume>138</volume>:<fpage>284</fpage>–<lpage>293</lpage>.</mixed-citation></ref>
<ref id="c10"><mixed-citation publication-type="journal"><string-name><surname>Coupé</surname> <given-names>P</given-names></string-name>, <string-name><surname>Manjón</surname> <given-names>JV</given-names></string-name>, <string-name><surname>Lanuza</surname> <given-names>E</given-names></string-name>, <string-name><surname>Catheline</surname> <given-names>G.</given-names></string-name> <article-title>Lifespan changes of the human brain in Alzheimer’s disease</article-title>. <source>Scientific Reports</source>. <year>2019</year>; <volume>9</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>12</lpage>.</mixed-citation></ref>
<ref id="c11"><mixed-citation publication-type="journal"><string-name><surname>Cuesta</surname> <given-names>P</given-names></string-name>, <string-name><surname>Garcés</surname> <given-names>P</given-names></string-name>, <string-name><surname>Castellanos</surname> <given-names>NP</given-names></string-name>, <string-name><surname>López</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Aurtenetxe</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bajo</surname> <given-names>R</given-names></string-name>, <string-name><surname>Pineda-Pardo</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Bruña</surname> <given-names>R</given-names></string-name>, <string-name><surname>Marín</surname> <given-names>AG</given-names></string-name>, <string-name><surname>Delgado</surname> <given-names>M</given-names></string-name>, <string-name><surname>Barabash</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ancín</surname> <given-names>I</given-names></string-name>, <string-name><surname>Cabranes</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Fernandez</surname> <given-names>A</given-names></string-name>,, <string-name><surname>Pozo</surname> <given-names>FD</given-names></string-name>, <string-name><surname>Sancho</surname> <given-names>M</given-names></string-name>, <string-name><surname>Marcos</surname> <given-names>A</given-names></string-name>, <string-name><surname>Nakamura</surname> <given-names>A</given-names></string-name>, <string-name><surname>Maestú</surname> <given-names>F.</given-names></string-name> <article-title>Influence of the APOE ε4 allele and mild cognitive impairment diagnosis in the disruption of the MEG resting state functional connectivity in sources space</article-title>. <source>Journal of Alzheimer’s Disease</source>. <year>2015</year>; <volume>44</volume>(<issue>2</issue>):<fpage>493</fpage>–<lpage>505</lpage>.</mixed-citation></ref>
<ref id="c12"><mixed-citation publication-type="journal"><string-name><surname>DeKosky</surname> <given-names>ST</given-names></string-name>, <string-name><surname>Scheff</surname> <given-names>SW</given-names></string-name>. <article-title>Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity</article-title>. <source>Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society</source>. <year>1990</year>; <volume>27</volume>(<issue>5</issue>):<fpage>457</fpage>–<lpage>464</lpage>.</mixed-citation></ref>
<ref id="c13"><mixed-citation publication-type="journal"><string-name><surname>DeTure</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Dickson</surname> <given-names>DW</given-names></string-name>. <article-title>The neuropathological diagnosis of Alzheimer’s disease</article-title>. <source>Molecular Neurodegeneration</source>. <year>2019</year>; <volume>14</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>18</lpage>.</mixed-citation></ref>
<ref id="c14"><mixed-citation publication-type="journal"><string-name><surname>Dubois</surname> <given-names>B</given-names></string-name>, <string-name><surname>Hampel</surname> <given-names>H</given-names></string-name>, <string-name><surname>Feldman</surname> <given-names>HH</given-names></string-name>, <string-name><surname>Scheltens</surname> <given-names>P</given-names></string-name>, <string-name><surname>Aisen</surname> <given-names>P</given-names></string-name>, <string-name><surname>Andrieu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bakardjian</surname> <given-names>H</given-names></string-name>, <string-name><surname>Benali</surname> <given-names>H</given-names></string-name>, <string-name><surname>Bertram</surname> <given-names>L</given-names></string-name>, <string-name><surname>Blennow</surname> <given-names>K</given-names></string-name>, <string-name><surname>Broich</surname> <given-names>K</given-names></string-name>, <string-name><surname>Cavedo</surname> <given-names>E</given-names></string-name>, <string-name><surname>Crutch</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dartigues</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Duyckaerts</surname> <given-names>C</given-names></string-name>, <string-name><surname>Epelbaum</surname> <given-names>S</given-names></string-name>, <string-name><surname>Frisoni</surname> <given-names>GB</given-names></string-name>, <string-name><surname>Gauthier</surname> <given-names>S</given-names></string-name>, <string-name><surname>Genthon</surname> <given-names>R</given-names></string-name>, <string-name><surname>Gouw</surname> <given-names>AA</given-names></string-name>, <etal>et al.</etal> <article-title>Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria</article-title>. <source>Alzheimer’s &amp; Dementia</source>. <year>2016</year>; <volume>12</volume>(<issue>3</issue>):<fpage>292</fpage>–<lpage>323</lpage>.</mixed-citation></ref>
<ref id="c15"><mixed-citation publication-type="journal"><string-name><surname>Echávarri</surname> <given-names>C</given-names></string-name>, <string-name><surname>Aalten</surname> <given-names>P</given-names></string-name>, <string-name><surname>Uylings</surname> <given-names>HB</given-names></string-name>, <string-name><surname>Jacobs</surname> <given-names>H</given-names></string-name>, <string-name><surname>Visser</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Gronenschild</surname> <given-names>E</given-names></string-name>, <string-name><surname>Verhey</surname> <given-names>F</given-names></string-name>, <string-name><surname>Burgmans</surname> <given-names>S.</given-names></string-name> <article-title>Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimer’s disease</article-title>. <source>Brain Structure and Function</source>. <year>2011</year>; <volume>215</volume>(<issue>3</issue>):<fpage>265</fpage>–<lpage>271</lpage>.</mixed-citation></ref>
<ref id="c16"><mixed-citation publication-type="journal"><string-name><surname>Engels</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hillebrand</surname> <given-names>A</given-names></string-name>, <string-name><surname>van der Flier</surname> <given-names>WM</given-names></string-name>, <string-name><surname>Stam</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Scheltens</surname> <given-names>P</given-names></string-name>, <string-name><surname>van Straaten</surname> <given-names>EC</given-names></string-name>. <article-title>Slowing of hippocampal activity correlates with cognitive decline in early onset Alzheimer’s disease</article-title>. <source>An MEG study with virtual electrodes. Frontiers in Human Neuroscience</source>. <year>2016</year>; <volume>10</volume>:<fpage>238</fpage>.</mixed-citation></ref>
<ref id="c17"><mixed-citation publication-type="journal"><string-name><surname>Fernández</surname> <given-names>A</given-names></string-name>, <string-name><surname>Hornero</surname> <given-names>R</given-names></string-name>, <string-name><surname>Mayo</surname> <given-names>A</given-names></string-name>, <string-name><surname>Poza</surname> <given-names>J</given-names></string-name>, <string-name><surname>Gil-Gregorio</surname> <given-names>P</given-names></string-name>, <string-name><surname>Ortiz</surname> <given-names>T.</given-names></string-name> <article-title>MEG spectral profile in Alzheimer’s disease and mild cognitive impairment</article-title>. <source>Clinical Neurophysiology</source>. <year>2006</year>; <volume>117</volume>(<issue>2</issue>):<fpage>306</fpage>–<lpage>314</lpage>.</mixed-citation></ref>
<ref id="c18"><mixed-citation publication-type="journal"><string-name><surname>Fonteijn</surname> <given-names>HM</given-names></string-name>, <string-name><surname>Modat</surname> <given-names>M</given-names></string-name>, <string-name><surname>Clarkson</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Barnes</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lehmann</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hobbs</surname> <given-names>NZ</given-names></string-name>, <string-name><surname>Scahill</surname> <given-names>RI</given-names></string-name>, <string-name><surname>Tabrizi</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Ourselin</surname> <given-names>S</given-names></string-name>, <string-name><surname>Fox</surname> <given-names>NC</given-names></string-name>, <string-name><surname>Alexander</surname> <given-names>DC</given-names></string-name>. <article-title>An event-based model for disease progression and its application in familial Alzheimer’s disease and Huntington’s disease</article-title>. <source>NeuroImage</source>. <year>2012</year>; <volume>60</volume>(<issue>3</issue>):<fpage>1880</fpage>–<lpage>1889</lpage>.</mixed-citation></ref>
<ref id="c19"><mixed-citation publication-type="other"><string-name><surname>Gaser</surname> <given-names>C</given-names></string-name>, <string-name><surname>Dahnke</surname> <given-names>R</given-names></string-name>, <string-name><surname>Thompson</surname> <given-names>PM</given-names></string-name>, <string-name><surname>Kurth</surname> <given-names>F</given-names></string-name>, <string-name><surname>Luders</surname> <given-names>E.</given-names></string-name> <article-title>CAT-a computational anatomy toolbox for the analysis of structural MRI data</article-title>. <source>BioRxiv</source>. <year>2022</year>; p. <fpage>2022</fpage>–<lpage>06</lpage>.</mixed-citation></ref>
<ref id="c20"><mixed-citation publication-type="journal"><string-name><surname>Hedden</surname> <given-names>T</given-names></string-name>, <string-name><surname>Van Dijk</surname> <given-names>KR</given-names></string-name>, <string-name><surname>Becker</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Mehta</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sperling</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Buckner</surname> <given-names>RL</given-names></string-name>. <article-title>Disruption of functional connectivity in clinically normal older adults harboring amyloid burden</article-title>. <source>Journal of Neuroscience</source>. <year>2009</year>; <volume>29</volume>(<issue>40</issue>):<fpage>12686</fpage>–<lpage>12694</lpage>.</mixed-citation></ref>
<ref id="c21"><mixed-citation publication-type="journal"><string-name><surname>Hipp</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Hawellek</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Corbetta</surname> <given-names>M</given-names></string-name>, <string-name><surname>Siegel</surname> <given-names>M</given-names></string-name>, <string-name><surname>Engel</surname> <given-names>AK</given-names></string-name>. <article-title>Large-scale cortical correlation structure of spontaneous oscillatory activity</article-title>. <source>Nature Neuroscience</source>. <year>2012</year>; <volume>15</volume>(<issue>6</issue>):<fpage>884</fpage>–<lpage>890</lpage>.</mixed-citation></ref>
<ref id="c22"><mixed-citation publication-type="journal"><string-name><surname>Hirata</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Matsuda</surname> <given-names>H</given-names></string-name>, <string-name><surname>Nemoto</surname> <given-names>K</given-names></string-name>, <string-name><surname>Ohnishi</surname> <given-names>T</given-names></string-name>, <string-name><surname>Hirao</surname> <given-names>K</given-names></string-name>, <string-name><surname>Yamashita</surname> <given-names>F</given-names></string-name>, <string-name><surname>Asada</surname> <given-names>T</given-names></string-name>, <string-name><surname>Iwabuchi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Samejima</surname> <given-names>H.</given-names></string-name> <article-title>Voxel-based morphometry to discriminate early Alzheimer’s disease from controls</article-title>. <source>Neuroscience Letters</source>. <year>2005</year>; <volume>382</volume>(<issue>3</issue>):<fpage>269</fpage>–<lpage>274</lpage>.</mixed-citation></ref>
<ref id="c23"><mixed-citation publication-type="journal"><string-name><surname>Hughes</surname> <given-names>LE</given-names></string-name>, <string-name><surname>Henson</surname> <given-names>RN</given-names></string-name>, <string-name><surname>Pereda</surname> <given-names>E</given-names></string-name>, Bruña R, <string-name><surname>López-Sanz</surname> <given-names>D</given-names></string-name>, <string-name><surname>Quinn</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Woolrich</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Nobre</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Rowe</surname> <given-names>JB</given-names></string-name>, <string-name><surname>Maestú</surname> <given-names>F.</given-names></string-name> <article-title>Biomagnetic biomarkers for dementia: A pilot multicentre study with a recommended methodological framework for magnetoencephalography</article-title>. <source>Alzheimer’s &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring</source>. <year>2019</year>; <volume>11</volume>:<fpage>450</fpage>–<lpage>462</lpage>.</mixed-citation></ref>
<ref id="c24"><mixed-citation publication-type="journal"><string-name><surname>Jack Jr</surname> <given-names>CR</given-names></string-name>, <string-name><surname>Bennett</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Blennow</surname> <given-names>K</given-names></string-name>, <string-name><surname>Carrillo</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Dunn</surname> <given-names>B</given-names></string-name>, <string-name><surname>Haeberlein</surname> <given-names>SB</given-names></string-name>, <string-name><surname>Holtzman</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Jagust</surname> <given-names>W</given-names></string-name>, <string-name><surname>Jessen</surname> <given-names>F</given-names></string-name>, <string-name><surname>Karlawish</surname> <given-names>J</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>E</given-names></string-name>, <string-name><surname>Molinuevo</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Montine</surname> <given-names>T</given-names></string-name>, <string-name><surname>Phelps</surname> <given-names>C</given-names></string-name>, <string-name><surname>Rankin</surname> <given-names>KP</given-names></string-name>, <string-name><surname>Rowe</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Scheltens</surname> <given-names>P</given-names></string-name>, <string-name><surname>Siemers</surname> <given-names>E</given-names></string-name>, <string-name><surname>Snyder</surname> <given-names>HM</given-names></string-name>, <string-name><surname>Sperling</surname> <given-names>R.</given-names></string-name> <article-title>NIA-AA research framework: toward a biological definition of Alzheimer’s disease</article-title>. <source>Alzheimer’s &amp; Dementia</source>. <year>2018</year>; <volume>14</volume>(<issue>4</issue>):<fpage>535</fpage>–<lpage>562</lpage>.</mixed-citation></ref>
<ref id="c25"><mixed-citation publication-type="journal"><string-name><surname>Jack Jr</surname> <given-names>CR</given-names></string-name>, <string-name><surname>Knopman</surname> <given-names>DS</given-names></string-name>, <string-name><surname>Jagust</surname> <given-names>WJ</given-names></string-name>, <string-name><surname>Petersen</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Weiner</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Aisen</surname> <given-names>PS</given-names></string-name>, <string-name><surname>Shaw</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Vemuri</surname> <given-names>P</given-names></string-name>, <string-name><surname>Wiste</surname> <given-names>HJ</given-names></string-name>, <string-name><surname>Weigand</surname> <given-names>SD</given-names></string-name>, <string-name><surname>Lesnick</surname> <given-names>TG</given-names></string-name>, <string-name><surname>Pankratz</surname> <given-names>VS</given-names></string-name>, <string-name><surname>Donohue</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Trojanowski</surname> <given-names>JQ</given-names></string-name>. <article-title>Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers</article-title>. <source>The Lancet Neurology</source>. <year>2013</year>; <volume>12</volume>(<issue>2</issue>):<fpage>207</fpage>–<lpage>216</lpage>.</mixed-citation></ref>
<ref id="c26"><mixed-citation publication-type="journal"><string-name><surname>Jack Jr</surname> <given-names>CR</given-names></string-name>, <string-name><surname>Wiste</surname> <given-names>HJ</given-names></string-name>, <string-name><surname>Vemuri</surname> <given-names>P</given-names></string-name>, <string-name><surname>Weigand</surname> <given-names>SD</given-names></string-name>, <string-name><surname>Senjem</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Zeng</surname> <given-names>G</given-names></string-name>, <string-name><surname>Bernstein</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Gunter</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Pankratz</surname> <given-names>VS</given-names></string-name>, <string-name><surname>Aisen</surname> <given-names>PS</given-names></string-name>, <string-name><surname>Weiner</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Petersen</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Shaw</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Trojanowski</surname> <given-names>JQ</given-names></string-name>, <string-name><surname>Knopman</surname> <given-names>DS</given-names></string-name>. <article-title>Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease</article-title>. <source>Brain</source>. <year>2010</year>; <volume>133</volume>(<issue>11</issue>):<fpage>3336</fpage>–<lpage>3348</lpage>.</mixed-citation></ref>
<ref id="c27"><mixed-citation publication-type="journal"><string-name><surname>Jellinger</surname> <given-names>KA</given-names></string-name>. <article-title>Recent update on the heterogeneity of the Alzheimer’s disease spectrum</article-title>. <source>Journal of Neural Transmission</source>. <year>2022</year>; <volume>129</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>24</lpage>.</mixed-citation></ref>
<ref id="c28"><mixed-citation publication-type="journal"><string-name><surname>Jeong</surname> <given-names>J.</given-names></string-name> <article-title>EEG dynamics in patients with Alzheimer’s disease</article-title>. <source>Clinical Neurophysiology</source>. <year>2004</year>; <volume>115</volume>(<issue>7</issue>):<fpage>1490</fpage>–<lpage>1505</lpage>.</mixed-citation></ref>
<ref id="c29"><mixed-citation publication-type="journal"><string-name><surname>Koelewijn</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bompas</surname> <given-names>A</given-names></string-name>, <string-name><surname>Tales</surname> <given-names>A</given-names></string-name>, <string-name><surname>Brookes</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Muthukumaraswamy</surname> <given-names>SD</given-names></string-name>, <string-name><surname>Bayer</surname> <given-names>A</given-names></string-name>, <string-name><surname>Singh</surname> <given-names>KD</given-names></string-name>. <article-title>Alzheimer’s disease disrupts alpha and beta-band resting-state oscillatory network connectivity</article-title>. <source>Clinical Neurophysiology</source>. <year>2017</year>; <volume>128</volume>(<issue>11</issue>):<fpage>2347</fpage>–<lpage>2357</lpage>.</mixed-citation></ref>
<ref id="c30"><mixed-citation publication-type="journal"><string-name><surname>Matsuda</surname> <given-names>H</given-names></string-name>, <string-name><surname>Mizumura</surname> <given-names>S</given-names></string-name>, <string-name><surname>Nemoto</surname> <given-names>K</given-names></string-name>, <string-name><surname>Yamashita</surname> <given-names>F</given-names></string-name>, <string-name><surname>Imabayashi</surname> <given-names>E</given-names></string-name>, <string-name><surname>Sato</surname> <given-names>N</given-names></string-name>, <string-name><surname>Asada</surname> <given-names>T.</given-names></string-name> <article-title>Automatic voxel-based mor-phometry of structural MRI by SPM8 plus diffeomorphic anatomic registration through exponentiated lie algebra improves the diagnosis of probable Alzheimer Disease</article-title>. <source>American Journal of Neuroradiology</source>. <year>2012</year>; <volume>33</volume>(<issue>6</issue>):<fpage>1109</fpage>–<lpage>1114</lpage>.</mixed-citation></ref>
<ref id="c31"><mixed-citation publication-type="journal"><string-name><surname>Matsuda</surname> <given-names>H.</given-names></string-name> <article-title>MRI morphometry in Alzheimer’s disease</article-title>. <source>Ageing Research Reviews</source>. <year>2016</year>; <volume>30</volume>:<fpage>17</fpage>–<lpage>24</lpage>.</mixed-citation></ref>
<ref id="c32"><mixed-citation publication-type="journal"><string-name><surname>McKhann</surname> <given-names>GM</given-names></string-name>, <string-name><surname>Knopman</surname> <given-names>DS</given-names></string-name>, <string-name><surname>Chertkow</surname> <given-names>H</given-names></string-name>, <string-name><surname>Hyman</surname> <given-names>BT</given-names></string-name>, <string-name><surname>Jack Jr</surname> <given-names>CR</given-names></string-name>, <string-name><surname>Kawas</surname> <given-names>CH</given-names></string-name>, <string-name><surname>Klunk</surname> <given-names>WE</given-names></string-name>, <string-name><surname>Koroshetz</surname> <given-names>WJ</given-names></string-name>, <string-name><surname>Manly</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Mayeux</surname> <given-names>R</given-names></string-name>, <string-name><surname>Mohs</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Morris</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Rossor</surname> <given-names>MN</given-names></string-name>, <string-name><surname>Scheltens</surname> <given-names>P</given-names></string-name>, <string-name><surname>Carrillo</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Thies</surname> <given-names>B</given-names></string-name>, <string-name><surname>Weintraub</surname> <given-names>S</given-names></string-name>, <string-name><surname>Phelps</surname> <given-names>CH</given-names></string-name>. <article-title>The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease</article-title>. <source>Alzheimer’s &amp; Dementia</source>. <year>2011</year>; <volume>7</volume>(<issue>3</issue>):<fpage>263</fpage>–<lpage>269</lpage>.</mixed-citation></ref>
<ref id="c33"><mixed-citation publication-type="journal"><string-name><surname>Meghdadi</surname> <given-names>AH</given-names></string-name>, <string-name><surname>Stevanović Karić</surname> <given-names>M</given-names></string-name>, <string-name><surname>McConnell</surname> <given-names>M</given-names></string-name>, <string-name><surname>Rupp</surname> <given-names>G</given-names></string-name>, <string-name><surname>Richard</surname> <given-names>C</given-names></string-name>, <string-name><surname>Hamilton</surname> <given-names>J</given-names></string-name>, <string-name><surname>Salat</surname> <given-names>D</given-names></string-name>, <string-name><surname>Berka</surname> <given-names>C.</given-names></string-name> <article-title>Resting state EEG biomarkers of cognitive decline associated with Alzheimer’s disease and mild cognitive impairment</article-title>. <source>PLOS ONE</source>. <year>2021</year>; <volume>16</volume>(<issue>2</issue>):<fpage>e0244180</fpage>.</mixed-citation></ref>
<ref id="c34"><mixed-citation publication-type="journal"><string-name><surname>Miller</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Celone</surname> <given-names>K</given-names></string-name>, <string-name><surname>DePeau</surname> <given-names>K</given-names></string-name>, <string-name><surname>Diamond</surname> <given-names>E</given-names></string-name>, <string-name><surname>Dickerson</surname> <given-names>BC</given-names></string-name>, <string-name><surname>Rentz</surname> <given-names>D</given-names></string-name>, <string-name><surname>Pihlajamäki</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sperling</surname> <given-names>RA</given-names></string-name>. <article-title>Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation</article-title>. <source>Proceedings of the National Academy of Sciences</source>. <year>2008</year>; <volume>105</volume>(<issue>6</issue>):<fpage>2181</fpage>–<lpage>2186</lpage>.</mixed-citation></ref>
<ref id="c35"><mixed-citation publication-type="journal"><string-name><surname>Nakamura</surname> <given-names>A</given-names></string-name>, <string-name><surname>Cuesta</surname> <given-names>P</given-names></string-name>, <string-name><surname>Fernández</surname> <given-names>A</given-names></string-name>, <string-name><surname>Arahata</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Iwata</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kuratsubo</surname> <given-names>I</given-names></string-name>, <string-name><surname>Bundo</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hattori</surname> <given-names>H</given-names></string-name>, <string-name><surname>Sakurai</surname> <given-names>T</given-names></string-name>, <string-name><surname>Fukuda</surname> <given-names>K</given-names></string-name>, <string-name><surname>Washimi</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Endo</surname> <given-names>H</given-names></string-name>, <string-name><surname>Takeda</surname> <given-names>A</given-names></string-name>, <string-name><surname>Diers</surname> <given-names>K</given-names></string-name>, <string-name><surname>Bajo</surname> <given-names>R</given-names></string-name>, <string-name><surname>Maestú</surname> <given-names>F</given-names></string-name>, <string-name><surname>Ito</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kato</surname> <given-names>T.</given-names></string-name> <article-title>Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer’s disease</article-title>. <source>Brain</source>. <year>2018</year>; <volume>141</volume>(<issue>5</issue>):<fpage>1470</fpage>–<lpage>1485</lpage>.</mixed-citation></ref>
<ref id="c36"><mixed-citation publication-type="journal"><string-name><surname>Nolte</surname> <given-names>G.</given-names></string-name> <article-title>The magnetic lead field theorem in the quasi-static approximation and its use for magnetoencephalography forward calculation in realistic volume conductors</article-title>. <source>Physics in Medicine &amp; Biology</source>. <year>2003</year>; <volume>48</volume>(<issue>22</issue>):<fpage>3637</fpage>.</mixed-citation></ref>
<ref id="c37"><mixed-citation publication-type="other"><string-name><surname>Oostenveld</surname> <given-names>R</given-names></string-name>, <string-name><surname>Fries</surname> <given-names>P</given-names></string-name>, <string-name><surname>Maris</surname> <given-names>E</given-names></string-name>, <string-name><surname>Schoffelen</surname> <given-names>JM</given-names></string-name>. <article-title>FieldTrip: open source software for advanced analysis of MEG, EEG, and invasive electrophysiological data</article-title>. <source>Computational Intelligence and Neuroscience</source>. <year>2011</year>; 2011.</mixed-citation></ref>
<ref id="c38"><mixed-citation publication-type="book"><string-name><surname>Penny</surname> <given-names>WD</given-names></string-name>, <string-name><surname>Friston</surname> <given-names>KJ</given-names></string-name>, <string-name><surname>Ashburner</surname> <given-names>JT</given-names></string-name>, <string-name><surname>Kiebel</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Nichols</surname> <given-names>TE</given-names></string-name>. <source>Statistical parametric mapping: the analysis of functional brain images</source>. <publisher-name>Elsevier</publisher-name>; <year>2011</year>.</mixed-citation></ref>
<ref id="c39"><mixed-citation publication-type="journal"><string-name><surname>Pusil</surname> <given-names>S</given-names></string-name>, <string-name><surname>López</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Cuesta</surname> <given-names>P</given-names></string-name>, <string-name><surname>Bruna</surname> <given-names>R</given-names></string-name>, <string-name><surname>Pereda</surname> <given-names>E</given-names></string-name>, <string-name><surname>Maestu</surname> <given-names>F.</given-names></string-name> <article-title>Hypersynchronization in mild cognitive impairment: the ‘X’model</article-title>. <source>Brain</source>. <year>2019</year>; <volume>142</volume>(<issue>12</issue>):<fpage>3936</fpage>–<lpage>3950</lpage>.</mixed-citation></ref>
<ref id="c40"><mixed-citation publication-type="journal"><string-name><surname>Ranasinghe</surname> <given-names>KG</given-names></string-name>, <string-name><surname>Cha</surname> <given-names>J</given-names></string-name>, <string-name><surname>Iaccarino</surname> <given-names>L</given-names></string-name>, <string-name><surname>Hinkley</surname> <given-names>LB</given-names></string-name>, <string-name><surname>Beagle</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Pham</surname> <given-names>J</given-names></string-name>, <string-name><surname>Jagust</surname> <given-names>WJ</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>BL</given-names></string-name>, <string-name><surname>Rankin</surname> <given-names>KP</given-names></string-name>, <string-name><surname>Rabinovici</surname> <given-names>GD</given-names></string-name>, <string-name><surname>Vossel</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Nagarajan</surname> <given-names>SS</given-names></string-name>. <article-title>Neurophysiological signatures in Alzheimer’s disease are distinctly associated with TAU, amyloid-β accumulation, and cognitive decline</article-title>. <source>Science Translational Medicine</source>. <year>2020</year>; <volume>12</volume>(<issue>534</issue>):<fpage>eaaz4069</fpage>.</mixed-citation></ref>
<ref id="c41"><mixed-citation publication-type="journal"><string-name><surname>Ranasinghe</surname> <given-names>KG</given-names></string-name>, <string-name><surname>Hinkley</surname> <given-names>LB</given-names></string-name>, <string-name><surname>Beagle</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Mizuiri</surname> <given-names>D</given-names></string-name>, <string-name><surname>Honma</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Welch</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Hubbard</surname> <given-names>I</given-names></string-name>, <string-name><surname>Mandelli</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>ZA</given-names></string-name>, <string-name><surname>Garrett</surname> <given-names>C</given-names></string-name>, <string-name><surname>La</surname> <given-names>A</given-names></string-name>, <string-name><surname>Boxer</surname> <given-names>AL</given-names></string-name>, <string-name><surname>Houde</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>BL</given-names></string-name>, <string-name><surname>Vossel</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Gorno-Tempini</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Nagarajan</surname> <given-names>SS</given-names></string-name>. <article-title>Distinct spa-tiotemporal patterns of neuronal functional connectivity in primary progressive aphasia variants</article-title>. <source>Brain</source>. <year>2017</year>; <volume>140</volume>(<issue>10</issue>):<fpage>2737</fpage>–<lpage>2751</lpage>.</mixed-citation></ref>
<ref id="c42"><mixed-citation publication-type="journal"><string-name><surname>Ranasinghe</surname> <given-names>KG</given-names></string-name>, <string-name><surname>Kudo</surname> <given-names>K</given-names></string-name>, <string-name><surname>Hinkley</surname> <given-names>L</given-names></string-name>, <string-name><surname>Beagle</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lerner</surname> <given-names>H</given-names></string-name>, <string-name><surname>Mizuiri</surname> <given-names>D</given-names></string-name>, <string-name><surname>Findlay</surname> <given-names>A</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>BL</given-names></string-name>, <string-name><surname>Kramer</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Gorno-Tempini</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Rabinovici</surname> <given-names>GD</given-names></string-name>, <string-name><surname>Rankin</surname> <given-names>KP</given-names></string-name>, <string-name><surname>Garcia</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Kirsch</surname> <given-names>HE</given-names></string-name>, <string-name><surname>Vossel</surname> <given-names>K</given-names></string-name>, <string-name><surname>Nagarajan</surname> <given-names>SS</given-names></string-name>. <article-title>Neuronal synchrony abnormalities associated with subclinical epileptiform activity in early-onset Alzheimer’s disease</article-title>. <source>Brain</source>. <year>2022</year>; <volume>145</volume>(<issue>2</issue>):<fpage>744</fpage>–<lpage>753</lpage>.</mixed-citation></ref>
<ref id="c43"><mixed-citation publication-type="journal"><string-name><surname>Ranasinghe</surname> <given-names>KG</given-names></string-name>, <string-name><surname>Petersen</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kudo</surname> <given-names>K</given-names></string-name>, <string-name><surname>Mizuiri</surname> <given-names>D</given-names></string-name>, <string-name><surname>Rankin</surname> <given-names>KP</given-names></string-name>, <string-name><surname>Rabinovici</surname> <given-names>GD</given-names></string-name>, <string-name><surname>Gorno-Tempini</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Seeley</surname> <given-names>WW</given-names></string-name>, <string-name><surname>Spina</surname> <given-names>S</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>BL</given-names></string-name>, <string-name><surname>Vossel</surname> <given-names>K</given-names></string-name>, <string-name><surname>Grinberg</surname> <given-names>LT</given-names></string-name>, <string-name><surname>Nagarajan</surname> <given-names>SS</given-names></string-name>. <article-title>Reduced synchrony in alpha oscillations during life predicts post mortem neurofibrillary tangle density in early-onset and atypical Alzheimer’s disease</article-title>. <source>Alzheimer’s &amp; Dementia</source>. <year>2021</year>; <volume>17</volume>(<issue>12</issue>):<fpage>2009</fpage>–<lpage>2019</lpage>.</mixed-citation></ref>
<ref id="c44"><mixed-citation publication-type="journal"><string-name><surname>Ranasinghe</surname> <given-names>KG</given-names></string-name>, <string-name><surname>Verma</surname> <given-names>P</given-names></string-name>, <string-name><surname>Cai</surname> <given-names>C</given-names></string-name>, <string-name><surname>Xie</surname> <given-names>X</given-names></string-name>, <string-name><surname>Kudo</surname> <given-names>K</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>X</given-names></string-name>, <string-name><surname>Lerner</surname> <given-names>H</given-names></string-name>, <string-name><surname>Mizuiri</surname> <given-names>D</given-names></string-name>, <string-name><surname>Strom</surname> <given-names>A</given-names></string-name>, <string-name><surname>Iaccarino</surname> <given-names>L</given-names></string-name>, <string-name><surname>La Joie</surname> <given-names>R</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>BL</given-names></string-name>, <string-name><surname>Gorno-Tempini</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Rankin</surname> <given-names>KP</given-names></string-name>, <string-name><surname>Jagust</surname> <given-names>WJ</given-names></string-name>, <string-name><surname>Vossel</surname> <given-names>K</given-names></string-name>, <string-name><surname>Rabinovici</surname> <given-names>GD</given-names></string-name>, <string-name><surname>Raj</surname> <given-names>A</given-names></string-name>, <string-name><surname>Nagarajan</surname> <given-names>SS</given-names></string-name>. <article-title>Altered excitatory and inhibitory neuronal subpopulation parameters are distinctly associated with tau and amyloid in Alzheimer’s disease</article-title>. <source>Elife</source>. <year>2022</year>; <volume>11</volume>:<fpage>e77850</fpage>.</mixed-citation></ref>
<ref id="c45"><mixed-citation publication-type="journal"><string-name><surname>Rolls</surname> <given-names>ET</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>CP</given-names></string-name>, <string-name><surname>Feng</surname> <given-names>J</given-names></string-name>, <string-name><surname>Joliot</surname> <given-names>M.</given-names></string-name> <article-title>Automated anatomical labelling atlas 3</article-title>. <source>Neuroimage</source>. <year>2020</year>; <volume>206</volume>:<fpage>116189</fpage>.</mixed-citation></ref>
<ref id="c46"><mixed-citation publication-type="journal"><string-name><surname>Sahoo</surname> <given-names>B</given-names></string-name>, <string-name><surname>Pathak</surname> <given-names>A</given-names></string-name>, <string-name><surname>Deco</surname> <given-names>G</given-names></string-name>, <string-name><surname>Banerjee</surname> <given-names>A</given-names></string-name>, <string-name><surname>Roy</surname> <given-names>D.</given-names></string-name> <article-title>Lifespan associated global patterns of coherent neural communication</article-title>. <source>Neuroimage</source>. <year>2020</year>; <volume>216</volume>:<fpage>116824</fpage>.</mixed-citation></ref>
<ref id="c47"><mixed-citation publication-type="journal"><string-name><surname>Scahill</surname> <given-names>RI</given-names></string-name>, <string-name><surname>Schott</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Stevens</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Rossor</surname> <given-names>MN</given-names></string-name>, <string-name><surname>Fox</surname> <given-names>NC</given-names></string-name>. <article-title>Mapping the evolution of regional atrophy in Alzheimer’s disease: unbiased analysis of fluid-registered serial MRI</article-title>. <source>Proceedings of the National Academy of Sciences</source>. <year>2002</year>; <volume>99</volume>(<issue>7</issue>):<fpage>4703</fpage>–<lpage>4707</lpage>.</mixed-citation></ref>
<ref id="c48"><mixed-citation publication-type="journal"><string-name><surname>Schoonhoven</surname> <given-names>DN</given-names></string-name>, <string-name><surname>Briels</surname> <given-names>CT</given-names></string-name>, <string-name><surname>Hillebrand</surname> <given-names>A</given-names></string-name>, <string-name><surname>Scheltens</surname> <given-names>P</given-names></string-name>, <string-name><surname>Stam</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Gouw</surname> <given-names>AA</given-names></string-name>. <article-title>Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease</article-title>. <source>Alzheimer’s Research &amp; Therapy</source>. <year>2022</year>; <volume>14</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>19</lpage>.</mixed-citation></ref>
<ref id="c49"><mixed-citation publication-type="journal"><string-name><surname>Sekihara</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kawabata</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ushio</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sumiya</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kawabata</surname> <given-names>S</given-names></string-name>, <string-name><surname>Adachi</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Nagarajan</surname> <given-names>SS</given-names></string-name>. <article-title>Dual signal subspace projection (DSSP): a novel algorithm for removing large interference in biomagnetic measurements</article-title>. <source>Journal of Neural Engineering</source>. <year>2016</year>; <volume>13</volume>(<issue>3</issue>):<fpage>036007</fpage>.</mixed-citation></ref>
<ref id="c50"><mixed-citation publication-type="book"><string-name><surname>Sekihara</surname> <given-names>K</given-names></string-name>, <string-name><surname>Nagarajan</surname> <given-names>SS</given-names></string-name>. <source>Electromagnetic brain imaging: a bayesian perspective</source>. <publisher-name>Springer</publisher-name>; <year>2015</year>.</mixed-citation></ref>
<ref id="c51"><mixed-citation publication-type="journal"><string-name><surname>Sekihara</surname> <given-names>K</given-names></string-name>, <string-name><surname>Nagarajan</surname> <given-names>SS</given-names></string-name>, <string-name><surname>Poeppel</surname> <given-names>D</given-names></string-name>, <string-name><surname>Marantz</surname> <given-names>A.</given-names></string-name> <article-title>Asymptotic SNR of scalar and vector minimum-variance beamformers for neuromagnetic source reconstruction</article-title>. <source>IEEE Transactions on Biomedical Engineering</source>. <year>2004</year>; <volume>51</volume>(<issue>10</issue>):<fpage>1726</fpage>–<lpage>1734</lpage>.</mixed-citation></ref>
<ref id="c52"><mixed-citation publication-type="book"><string-name><surname>Sekihara</surname> <given-names>K</given-names></string-name>, <string-name><surname>Nagarajan</surname> <given-names>SS</given-names></string-name>. <source>Adaptive spatial filters for electromagnetic brain imaging</source>. <publisher-name>Springer Science &amp; Business Media</publisher-name>; <year>2008</year>.</mixed-citation></ref>
<ref id="c53"><mixed-citation publication-type="journal"><string-name><surname>Selkoe</surname> <given-names>DJ</given-names></string-name>. <article-title>Alzheimer’s disease is a synaptic failure</article-title>. <source>Science</source>. <year>2002</year>; <volume>298</volume>(<issue>5594</issue>):<fpage>789</fpage>–<lpage>791</lpage>.</mixed-citation></ref>
<ref id="c54"><mixed-citation publication-type="journal"><string-name><surname>Sperling</surname> <given-names>R</given-names></string-name>, <string-name><surname>Mormino</surname> <given-names>E</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>K.</given-names></string-name> <article-title>The evolution of preclinical Alzheimer’s disease: implications for prevention trials</article-title>. <source>Neuron</source>. <year>2014</year>; <volume>84</volume>(<issue>3</issue>):<fpage>608</fpage>–<lpage>622</lpage>.</mixed-citation></ref>
<ref id="c55"><mixed-citation publication-type="journal"><string-name><surname>Sperling</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Aisen</surname> <given-names>PS</given-names></string-name>, <string-name><surname>Beckett</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Bennett</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Craft</surname> <given-names>S</given-names></string-name>, <string-name><surname>Fagan</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Iwatsubo</surname> <given-names>T</given-names></string-name>, <string-name><surname>Jack Jr</surname> <given-names>CR</given-names></string-name>, <string-name><surname>Kaye</surname> <given-names>J</given-names></string-name>, <string-name><surname>Montine</surname> <given-names>TJ</given-names></string-name>, <string-name><surname>Park</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Reiman</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Rowe</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Siemers</surname> <given-names>E</given-names></string-name>, <string-name><surname>Stern</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Yaffe</surname> <given-names>K</given-names></string-name>, <string-name><surname>Carrillo</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Thies</surname> <given-names>B</given-names></string-name>, <string-name><surname>Morrison-Bogorad</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wagster</surname> <given-names>MV</given-names></string-name>, <etal>et al.</etal> <article-title>Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease</article-title>. <source>Alzheimer’s &amp; Dementia</source>. <year>2011</year>; <volume>7</volume>(<issue>3</issue>):<fpage>280</fpage>–<lpage>292</lpage>.</mixed-citation></ref>
<ref id="c56"><mixed-citation publication-type="journal"><string-name><surname>Spires-Jones</surname> <given-names>TL</given-names></string-name>, <string-name><surname>Hyman</surname> <given-names>BT</given-names></string-name>. <article-title>The intersection of amyloid beta and tau at synapses in Alzheimer’s disease</article-title>. <source>Neuron</source>. <year>2014</year>; <volume>82</volume>(<issue>4</issue>):<fpage>756</fpage>–<lpage>771</lpage>.</mixed-citation></ref>
<ref id="c57"><mixed-citation publication-type="journal"><string-name><surname>Stam</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Jones</surname> <given-names>B</given-names></string-name>, <string-name><surname>Manshanden</surname> <given-names>I</given-names></string-name>, <string-name><given-names>Van Walsum</given-names> <surname>AvC</surname></string-name>, <string-name><surname>Montez</surname> <given-names>T</given-names></string-name>, <string-name><surname>Verbunt</surname> <given-names>JP</given-names></string-name>, <string-name><surname>de Munck</surname> <given-names>JC</given-names></string-name>, <string-name><surname>van Dijk</surname> <given-names>BW</given-names></string-name>, <string-name><surname>Berendse</surname> <given-names>HW</given-names></string-name>, <string-name><surname>Scheltens</surname> <given-names>P.</given-names></string-name> <article-title>Magnetoencephalographic evaluation of resting-state functional connectivity in Alzheimer’s disease</article-title>. <source>Neuroimage</source>. <year>2006</year>; <volume>32</volume>(<issue>3</issue>):<fpage>1335</fpage>–<lpage>1344</lpage>.</mixed-citation></ref>
<ref id="c58"><mixed-citation publication-type="journal"><string-name><surname>Teipel</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Pruessner</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Faltraco</surname> <given-names>F</given-names></string-name>, <string-name><surname>Born</surname> <given-names>C</given-names></string-name>, <string-name><surname>Rocha-Unold</surname> <given-names>M</given-names></string-name>, <string-name><surname>Evans</surname> <given-names>A</given-names></string-name>, <string-name><surname>Möller</surname> <given-names>HJ</given-names></string-name>, <string-name><surname>Hampel</surname> <given-names>H.</given-names></string-name> <article-title>Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI</article-title>. <source>Journal of Neurology</source>. <year>2006</year>; <volume>253</volume>(<issue>6</issue>):<fpage>794</fpage>–<lpage>800</lpage>.</mixed-citation></ref>
<ref id="c59"><mixed-citation publication-type="journal"><string-name><surname>Terry</surname> <given-names>RD</given-names></string-name>, <string-name><surname>Masliah</surname> <given-names>E</given-names></string-name>, <string-name><surname>Salmon</surname> <given-names>DP</given-names></string-name>, <string-name><surname>Butters</surname> <given-names>N</given-names></string-name>, <string-name><surname>DeTeresa</surname> <given-names>R</given-names></string-name>, <string-name><surname>Hill</surname> <given-names>R</given-names></string-name>, <string-name><surname>Hansen</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Katzman</surname> <given-names>R.</given-names></string-name> <article-title>Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment</article-title>. <source>Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society</source>. <year>1991</year>; <volume>30</volume>(<issue>4</issue>):<fpage>572</fpage>–<lpage>580</lpage>.</mixed-citation></ref>
<ref id="c60"><mixed-citation publication-type="journal"><string-name><surname>Tondelli</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wilcock</surname> <given-names>GK</given-names></string-name>, <string-name><surname>Nichelli</surname> <given-names>P</given-names></string-name>, <string-name><surname>De Jager</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Jenkinson</surname> <given-names>M</given-names></string-name>, <string-name><surname>Zamboni</surname> <given-names>G.</given-names></string-name> <article-title>Structural MRI changes detectable up to ten years before clinical Alzheimer’s disease</article-title>. <source>Neurobiology of Aging</source>. <year>2012</year>; <volume>33</volume>(<issue>4</issue>):<fpage>825</fpage>.e25–36.</mixed-citation></ref>
<ref id="c61"><mixed-citation publication-type="journal"><string-name><surname>Tsoi</surname> <given-names>KK</given-names></string-name>, <string-name><surname>Chan</surname> <given-names>JY</given-names></string-name>, <string-name><surname>Hirai</surname> <given-names>HW</given-names></string-name>, <string-name><surname>Wong</surname> <given-names>SY</given-names></string-name>, <string-name><surname>Kwok</surname> <given-names>TC</given-names></string-name>. <article-title>Cognitive tests to detect dementia: a systematic review and meta-analysis</article-title>. <source>JAMA Internal Medicine</source>. <year>2015</year>; <volume>175</volume>(<issue>9</issue>):<fpage>1450</fpage>–<lpage>1458</lpage>.</mixed-citation></ref>
<ref id="c62"><mixed-citation publication-type="journal"><string-name><surname>Vogel</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Young</surname> <given-names>AL</given-names></string-name>, <string-name><surname>Oxtoby</surname> <given-names>NP</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ossenkoppele</surname> <given-names>R</given-names></string-name>, <string-name><surname>Strandberg</surname> <given-names>OT</given-names></string-name>, <string-name><surname>La Joie</surname> <given-names>R</given-names></string-name>, <string-name><surname>Aksman</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Grothe</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Iturria-Medina</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Initiative</surname> <given-names>ADN</given-names></string-name>, <string-name><surname>Pontecorvo</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Devous</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Rabinovici</surname> <given-names>GD</given-names></string-name>, <string-name><surname>Alexander</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Lyoo</surname> <given-names>CH</given-names></string-name>, <string-name><surname>Evans</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Hansson</surname> <given-names>O.</given-names></string-name> <article-title>Four distinct trajectories of tau deposition identified in Alzheimer’s disease</article-title>. <source>Nature Medicine</source>. <year>2021</year>; <volume>27</volume>(<issue>5</issue>):<fpage>871</fpage>–<lpage>881</lpage>.</mixed-citation></ref>
<ref id="c63"><mixed-citation publication-type="other"><string-name><surname>Wiesman</surname> <given-names>AI</given-names></string-name>, <string-name><surname>Castanheira</surname> <given-names>JDS</given-names></string-name>, <string-name><surname>Baillet</surname> <given-names>S.</given-names></string-name> <article-title>Stability of spectral estimates in resting-state magnetoencephalography: recommendations for minimal data duration with neuroanatomical specificity</article-title>. <source>NeuroImage</source>. <year>2021</year>; p. <fpage>118823</fpage>.</mixed-citation></ref>
<ref id="c64"><mixed-citation publication-type="journal"><string-name><surname>Wiesman</surname> <given-names>AI</given-names></string-name>, <string-name><surname>Murman</surname> <given-names>DL</given-names></string-name>, <string-name><surname>May</surname> <given-names>PE</given-names></string-name>, <string-name><surname>Schantell</surname> <given-names>M</given-names></string-name>, <string-name><surname>Losh</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>HJ</given-names></string-name>, <string-name><surname>Willet</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Eastman</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Christopher-Hayes</surname> <given-names>NJ</given-names></string-name>, <string-name><surname>Knott</surname> <given-names>NL</given-names></string-name>, <string-name><surname>Houseman</surname> <given-names>LL</given-names></string-name>, <string-name><surname>Wolfson</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Losh</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Wilson</surname> <given-names>TW</given-names></string-name>. <article-title>Spatio-spectral relationships between pathological neural dynamics and cognitive impairment along the Alzheimer’s disease spectrum</article-title>. <source>Alzheimer’s &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring</source>. <year>2021</year>; <volume>13</volume>(<issue>1</issue>):<fpage>e12200</fpage>.</mixed-citation></ref>
<ref id="c65"><mixed-citation publication-type="journal"><string-name><surname>Xia</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>J</given-names></string-name>, <string-name><surname>He</surname> <given-names>Y.</given-names></string-name> <article-title>BrainNet Viewer: a network visualization tool for human brain connectomics</article-title>. <source>PLOS ONE</source>. <year>2013</year>; <volume>8</volume>(<issue>7</issue>):<fpage>e68910</fpage>.</mixed-citation></ref>
<ref id="c66"><mixed-citation publication-type="journal"><string-name><surname>Young</surname> <given-names>AL</given-names></string-name>, <string-name><surname>Marinescu</surname> <given-names>RV</given-names></string-name>, <string-name><surname>Oxtoby</surname> <given-names>NP</given-names></string-name>, <string-name><surname>Bocchetta</surname> <given-names>M</given-names></string-name>, <string-name><surname>Yong</surname> <given-names>K</given-names></string-name>, <string-name><surname>Firth</surname> <given-names>NC</given-names></string-name>, <string-name><surname>Cash</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Thomas</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Dick</surname> <given-names>KM</given-names></string-name>, <string-name><surname>Cardoso</surname> <given-names>J</given-names></string-name>, <string-name><given-names>Swieten</given-names> <surname>Jv</surname></string-name>, <string-name><surname>Borroni</surname> <given-names>B</given-names></string-name>, <string-name><surname>Galimberti</surname> <given-names>D</given-names></string-name>, <string-name><surname>Masellis</surname> <given-names>M</given-names></string-name>, <string-name><surname>Tartaglia</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Rowe</surname> <given-names>JB</given-names></string-name>, <string-name><surname>Graff</surname> <given-names>C</given-names></string-name>, <string-name><surname>Tagliavini</surname> <given-names>F</given-names></string-name>, <string-name><surname>Frisoni</surname> <given-names>GB</given-names></string-name>, <string-name><surname>Laforce Jr</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal> <article-title>Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference</article-title>. <source>Nature Communications</source>. <year>2018</year>; <volume>9</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>16</lpage>.</mixed-citation></ref>
<ref id="c67"><mixed-citation publication-type="journal"><string-name><surname>Young</surname> <given-names>AL</given-names></string-name>, <string-name><surname>Oxtoby</surname> <given-names>NP</given-names></string-name>, <string-name><surname>Daga</surname> <given-names>P</given-names></string-name>, <string-name><surname>Cash</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Fox</surname> <given-names>NC</given-names></string-name>, <string-name><surname>Ourselin</surname> <given-names>S</given-names></string-name>, <string-name><surname>Schott</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Alexander</surname> <given-names>DC</given-names></string-name>. <article-title>A data-driven model of biomarker changes in sporadic Alzheimer’s disease</article-title>. <source>Brain</source>. <year>2014</year>; <volume>137</volume>(<issue>9</issue>):<fpage>2564</fpage>–<lpage>2577</lpage>.</mixed-citation></ref>
<ref id="c68"><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname> <given-names>L</given-names></string-name>, <string-name><surname>McInnes</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wierda</surname> <given-names>K</given-names></string-name>, <string-name><surname>Holt</surname> <given-names>M</given-names></string-name>, <string-name><surname>Herrmann</surname> <given-names>AG</given-names></string-name>, <string-name><surname>Jackson</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>YC</given-names></string-name>, <string-name><surname>Swerts</surname> <given-names>J</given-names></string-name>, <string-name><surname>Beyens</surname> <given-names>J</given-names></string-name>, <string-name><surname>Miskiewicz</surname> <given-names>K</given-names></string-name>, <string-name><surname>Vilain</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dewachter</surname> <given-names>I</given-names></string-name>, <string-name><surname>Moechars</surname> <given-names>D</given-names></string-name>, <string-name><surname>De Strooper</surname> <given-names>B</given-names></string-name>, <string-name><surname>Spires-Jones</surname> <given-names>TL</given-names></string-name>, <string-name><surname>De Wit</surname> <given-names>J</given-names></string-name>, <string-name><surname>Verstreken</surname> <given-names>P.</given-names></string-name> <article-title>Tau association with synaptic vesicles causes presynaptic dysfunction</article-title>. <source>Nature Communications</source>. <year>2017</year>; <volume>8</volume>(<issue>1</issue>):<fpage>15295</fpage>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.91044.1.sa2</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Herrmann</surname>
<given-names>Björn</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Baycrest Hospital</institution>
</institution-wrap>
<city>Toronto</city>
<country>Canada</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Important</kwd>
</kwd-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Solid</kwd>
</kwd-group>
</front-stub>
<body>
<p>This work presents <bold>important</bold> findings for the field of Alzheimer's disease, especially for the electrophysiology subfield, by investigating the temporal evolution of different disease stages typically reported using M/EEG markers of resting-state brain activity. The evidence supporting the conclusions is <bold>solid</bold> and the methodology as well as the descriptions of the processes are of high quality, although a separation of individuals who are biomarker positive versus negative would have strengthened the interpretability of the results and the conclusions of the study.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.91044.1.sa1</article-id>
<title-group>
<article-title>Reviewer #1 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>
The authors aimed to infer the trajectories of long range and local neuronal synchrony across the Alzheimer's disease continuum, relative to neurodegeneration and cognitive decline. The trajectories are inferred using event-based models, which infer a set of data-driven disease stages from a given dataset. The authors develop an adapted event-based modelling approach, in which they characterise each stage as a particular biomarker increasing by a particular z-score deviation from controls. Fitting infers the optimal set of z-scores to use for each biomarker and the order in which each biomarker reaches each z-score. The authors apply this approach to data from 148 individuals (70 cognitively unimpaired older adults and 78 individual with mild cognitive impairment or Alzheimer's disease), identifying trajectories in which long-range (amplitude-envolope correlation) and local (regional spectral power) neuronal synchrony in the alpha and beta bands becomes abnormal prior to neurodegeneration (measured as the volume of the parahippocampal gyrus) and cognitive decline (measured using the mini-mental state examination).</p>
<p>Strengths:</p>
<p>
- The main strength is that the authors assess two models. In the first they derive a staging system based only on the volume of the parahippocampal gyrus and mini-mental state examination score. They then investigate how neuronal synchrony metrics change compared to this staging system. In the second they derive a staging system that also includes an average (combined long-range and local) neuronal synchrony metric and investigate how long-range and local synchrony metrics change relative to this staging system. This is a strength as the first model provides confidence that there is not overfitting to the neuronal synchrony data, and the second provides more detailed insights into the dynamics of the early neuronal synchrony changes.</p>
<p>
- Another strength is that the authors automatically infer the optimal z-scores to choose, rather than having to pre-select them manually, as in previous approaches.</p>
<p>Weaknesses:</p>
<p>
- The dataset is small and no external validation is performed.</p>
<p>
- A high proportion of the data is from controls (nearly 50%) with no biomarker evidence of Alzheimer's disease, and so the changes may be driven by aging or other non-Alzheimer's effects.</p>
<p>
- Inferring the optimal z-scores is a strength, however as different sets of z-scores are allowed per biomarker, there is a concern that the changes reflected are mainly driven by the choice of z-score, rather than the markers themselves (e.g. if lower z-scores are selected for one marker than another, then changes in that marker will appear to be detected earlier, even if both markers change at the same time).</p>
<p>
- In equation 2 it is unclear why the gaussian is measured based on a sum over I. The more obvious choice would be to use a multivariate gaussian with no covariance, which would mean taking the product rather than the sum over I.</p>
<p>
- In the original event-based model, k is a hidden variable. Presumably that is also the case here, however the notation k=stage(j) makes it seem like each subject is assigned a stage during the sequence optimisation.</p>
<p>
- Typically for event-based modelling, positional variance diagrams are created from the markov chain monte carlo samples of the event sequence, enabling visualisation of the uncertainty in the sequence, but these are not included in the study.</p>
<p>
- Many of the figures in the manuscript (e.g. Figure 1E/G, Figure 2A/B, Figure 3A/B/E/F/I/J, Figure 4 A/B/E/F/I/J) are based on averages in both the x and the y axis. In the x dimension, individuals have a weighted contribution to the value on the y axis, depending on their stage probability. In the y dimension, the values are averages across those individuals, and the error bars represent the standard error rather than the standard deviation. Whilst the trajectories themselves are interesting, they may not be discriminative at the individual level and may be more heterogeneous than it appears.</p>
<p>
- The bootstrapped statistical analyses comparing metrics between the stages do not consider the variability in the sequence.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.91044.1.sa0</article-id>
<title-group>
<article-title>Reviewer #2 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary: This work presented by Kudo and colleagues is of great importance to strengthen our understanding of electrophysiological changes in the course of AD. Although the main conclusions regarding functional connectivity and spectral power change through the course of the disease are not new and have been largely studied and theorised on, this article offers an innovative approach that certainly consolidates previous knowledge on the topic. Not only that, this article also broadens our knowledge presenting useful and important details on the specificity of frequency and cortical distribution of these early alterations. The main take-home message of this work is the early disruption of electrophysiological signatures that precedes detectable alterations in other more commonly used pathology markers (i.e. gray matter atrophy and cognitive impairment). More specifically, these signatures include long-range connectivity in the alpha and beta bands, and local synchrony (spectral power) in the same frequency bands.</p>
<p>Strengths: The present work has some major strengths that make it paramount for the advance of our understanding of AD electrophysiology. It is a very well written manuscript that, despite the complexity of the analyses employed, runs the reader through the different steps of the analysis in a pedagogic and clever way, making the points raised by the results easy to grasp. The methodology itself is carefully chosen and appropriate to the nature of the question posed by the researchers, as event-based models are well-suited for cross-sectional data.</p>
<p>The quality of the figures is outstanding; not only are they aesthetic but, more importantly, the figures convey information exceptionally well and facilitate comprehension of the main results.</p>
<p>
The conclusions of the paper are, in general, well described and discussed, and consider the state-of-the-art works of AD electrophysiology. Furthermore, even though the conclusions themselves are not groundbreaking at all (synaptic damage preceding structural and cognitive impairment is one of the epitomes of the pathological cascading model proposed by Jack in 2010), this article is innovative and groundbreaking in the way they address with clever analyses in a relatively large sample for neuroimaging standards.</p>
<p>Weaknesses: The main limitation of the work revolves around sample definition and inclusion criteria that are somewhat confusing obscuring some of the points of the analyses. Firstly it is not clear why the purely clinical approach is employed to diagnose the &quot;probable Alzheimer´s Disease&quot; for the 78 participants in the &quot;AD group&quot;. In the same paragraph, it is stated that 67 out of the 78 participants show biomarker positivity, thus allowing a more biologically guided diagnosis that is preferred according to current NIA-AA criteria. This would avoid highly possible mixing of different subtypes of dementia etiologies. One might wonder, why would those 11 participants be included if we have strong indications that their symptoms are not due to AD? Furthermore, the real pathological status of the control group is somewhat questionable. The authors do not specify whether common AD biomarkers are available for this subgroup. In that case, it would have highly increased the clarity and interpretability of the results if this group was subdivided in a preclinical and completely healthy control group. This would be particularly interesting since a significant proportion of the control group is labeled as belonging to stages 2,3,4 (MCI) and even 5 (mild dementia). This raises the question of whether these participants are true healthy controls mislabeled by the EBM model, or actual cognitive controls with actual underlying AD pathology well identified by the model proposed. On this note, Figure 2 (C and D) and Figure 3 (C, G and K) show a cortical surface depicting the mean difference of each stage vs the control group, which again, is formed by subjects that can be included (and in fact, are included) in all of those stages, obscuring the meaning and interpretability of these cortical distributions.</p>
</body>
</sub-article>
</article>